Literatur

• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997; 94(33):A-2154-5.
• Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung (ÄZQ), et al. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2001)13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl. Fortbild. Qualitatssich. 2002; 96(Suppl III):3–60.
• Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das AWMF-Regelwerk Leitlinien. München: Zuckschwerdt; 2012.
• Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)-Ständige Kommission Leitlinien. AWMF-Regelwerk Leitlinien: Version 2.0. 2020 [cited: 2021-03-22]. http://www.awmf.org/leitlinien/awmf-regelwerk.html.
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Programm für Nationale VersorgungsLeitlinien - Methodenreport, 5. Auflage. Version 1. 2017 [cited: 2019-09-05]. DOI: 10.6101/AZQ/000169. http://doi.org/10.6101/AZQ/000169.
• Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490–7. http://www.ncbi.nlm.nih.gov/pubmed/15205295.
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650):924–6. http://www.ncbi.nlm.nih.gov/pubmed/18436948.
• Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Unipolare Depression – Leitlinienreport, Version 3.0. 2022 [cited: 2022-06-22]. DOI: 10.6101/AZQ/000488. http://doi.org/10.6101/AZQ/000488.
• Elliott R, Greenberg LS, Lietaer G. Research on experiential psychotherapies. In: Lambert MJ, editor. Bergin and Garfield's Handbook of Psychotherapy and Behavior Change. 5th. New York: Wiley; 2004, p. 493–540.
• Roth A, Fonagy P. What Works for Whom: A Critical Review of Psychotherapy Research. New York: Guilford; 1996.
• Lambert M, Ogles B. The efficacy and effectiveness of psychotherapy. In: Lambert MJ, editor. Bergin and Garfield's Handbook of Psychotherapy and Behavior Change. 5th. New York: Wiley; 2004, p. 139–193.
• Shadish WR, Matt GE, Navarro AM, et al. The effects of psychological therapies under clinically representative conditions: A meta-analysis. Psychol Bull. 2000; 126(4):512–29. DOI: 10.1037/0033-2909.126.4.512. http://www.ncbi.nlm.nih.gov/pubmed/10900994.
• Huhn M, Tardy M, Spineli LM, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: A systematic overview of meta-analyses. JAMA Psychiatry 2014; 71(6):706–15. DOI: 10.1001/jamapsychiatry.2014.112. http://www.ncbi.nlm.nih.gov/pubmed/24789675.
• Moncrieff J, Kirsch I. Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences. Contemp Clin Trials 2015; 43:60–2. DOI: 10.1016/j.cct.2015.05.005. http://www.ncbi.nlm.nih.gov/pubmed/25979317.
• Munkholm K, Paludan-Müller AS, Boesen K. Considering the methodological limitations in the evidence base of antidepressants for depression: A reanalysis of a network meta-analysis. BMJ Open 2019; 9(6):e024886. DOI: 10.1136/bmjopen-2018-024886. http://www.ncbi.nlm.nih.gov/pubmed/31248914.
• Hrobjartsson A, Gotzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2010(1):CD003974. DOI: 10.1002/14651858.CD003974.pub3. http://www.ncbi.nlm.nih.gov/pubmed/20091554.
• Dago PL, Quitkin FM. Role of the Placebo Response in the Treatment of Depressive Disorders. CNS. Drugs 1995; 4(5):335–40. DOI: 10.2165/00023210-199504050-00002.
• Kirsch I, Sapirstein G. Listening to prozac but hearing placebo: A meta-analysis of antidepressant medication. Prev Treatm 1998; 1(1).
• Kirsch I, Moore TJ, Scoboria A. The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treatm 2002; 5.
• Mora MS, Nestoriuc Y, Rief W. Lessons learned from placebo groups in antidepressant trials. Philos Trans R Soc Lond B Biol Sci 2011; 366(1572):1879–88. DOI: 10.1098/rstb.2010.0394. http://www.ncbi.nlm.nih.gov/pubmed/21576145.
• Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004(1):CD003012. http://www.ncbi.nlm.nih.gov/pubmed/14974002.
• National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Depression in Adults (update). Depression: The treatment and management of depression in adults. Draft for consultation Feb 2009. 2009 [cited: 2021-04-08]. http://www.nice.org.uk/nicemedia/pdf/DepressionUpdateFullGuidlineDraft.pdf.
• Furukawa TA, Noma H, Caldwell DM, et al. Waiting list may be a nocebo condition in psychotherapy trials: A contribution from network meta-analysis. Acta Psychiatr Scand 2014; 130(3):181–92. DOI: 10.1111/acps.12275. http://www.ncbi.nlm.nih.gov/pubmed/24697518.
• Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J Med 2008; 358(3):252–60. http://www.ncbi.nlm.nih.gov/pubmed/18199864.
• Cuijpers P, Smit F, Bohlmeijer E, et al. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: Meta-analytic study of publication bias. Br J Psychiatry 2010; 196(3):173–8. DOI: 10.1192/bjp.bp.109.066001. http://www.ncbi.nlm.nih.gov/pubmed/20194536.
• Niemeyer H, Musch J, Pietrowsky R. Publication bias in meta-analyses of the efficacy of psychotherapeutic interventions for depression. J Consult Clin Psychol 2013; 81(1):58–74. DOI: 10.1037/a0031152. http://www.ncbi.nlm.nih.gov/pubmed/23244368.
• Flint J, Cuijpers P, Horder J, et al. Is there an excess of significant findings in published studies of psychotherapy for depression? Psychol Med 2015; 45(2):439–46. DOI: 10.1017/S0033291714001421. http://www.ncbi.nlm.nih.gov/pubmed/25062429.
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006; 163(11):1905–17. http://www.ncbi.nlm.nih.gov/pubmed/17074942.
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178:234–41. http://www.ncbi.nlm.nih.gov/pubmed/11230034.
• Nordmo M, Monsen JT, Høglend PA, et al. Investigating the dose-response effect in open-ended psychotherapy. Psychother Res 2020:1–11. DOI: 10.1080/10503307.2020.1861359. http://www.ncbi.nlm.nih.gov/pubmed/33331244.
• Cuijpers P, Karyotaki E, Andersson G, et al. The effects of blinding on the outcomes of psychotherapy and pharmacotherapy for adult depression: A meta-analysis. Eur Psychiatry 2015; 30(6):685–93. DOI: 10.1016/j.eurpsy.2015.06.005. http://www.ncbi.nlm.nih.gov/pubmed/26169475.
• Falkai P, Wittchen HU, Doepfner M, et al., editors. Diagnostische Kriterien DSM-5. 2nd ed. Göttingen: Hogrefe; 2020.
• Ahrens B, Freyberger HJ. Diagnostik affektiver Störungen in der Praxis-Beitrag der ICD-10. MMW Munch Med Wochenschr 1998; 140(11):37–41.
• Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. Lancet 2006; 367(9505):153–67. http://www.ncbi.nlm.nih.gov/pubmed/16413879.
• Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: Results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 1998; 33(12):587–95. http://www.ncbi.nlm.nih.gov/pubmed/9857791.
• Busch MA, Maske UE, Ryl L, et al. Prävalenz von depressiver Symptomatik und diagnostizierter Depression bei Erwachsenen in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56(5-6):733–9. DOI: 10.1007/s00103-013-1688-3. http://www.ncbi.nlm.nih.gov/pubmed/23703492.
• Jacobi F, Höfler M, Strehle J, et al. Psychische Störungen in der Allgemeinbevölkerung: Studie zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul Psychische Gesundheit (DEGS1-MH). Nervenarzt 2014; 85(1):77–87. DOI: 10.1007/s00115-013-3961-y. http://www.ncbi.nlm.nih.gov/pubmed/24441882.
• Jacobi F, Höfler M, Strehle J, et al. Erratum zu: Psychische Störungen in der Allgemeinbevölkerung. Studie zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul "Psychische Gesundheit" (DEGS1-MH). Nervenarzt 2016; 87(1):88–90. DOI: 10.1007/s00115-015-4458-7. http://www.ncbi.nlm.nih.gov/pubmed/26601984.
• Streit F, Zillich L, Frank J, et al. Lifetime and current depression in the German National Cohort (NAKO). World J Biol Psychiatry 2021:1–31. DOI: 10.1080/15622975.2021.2014152. http://www.ncbi.nlm.nih.gov/pubmed/34870540.
• Robert Koch-Institut (RKI). BGS98: Bundes-Gesundheitssurvey 1998. Gesundh Wesen 1999; 61(2 Suppl):S55–S222.
• Bretschneider J, Janitza S, Jacobi F, et al. Time trends in depression prevalence and health-related correlates: Results from population-based surveys in Germany 1997-1999 vs. 2009-2012. BMC Psychiatry 2018; 18(1):394. DOI: 10.1186/s12888-018-1973-7. http://www.ncbi.nlm.nih.gov/pubmed/30572872.
• Steffen A, Holstiege J, Akmatov MK, et al. Zeitliche Trends in der Diagnoseprävalenz depressiver Störungen: eine Analyse auf Basis bundesweiter vertragsärztlicher Abrechnungsdaten der Jahr 2009 bis 2017. 2019 (Versorgungsatlas-Bericht; Nr. 19/05) [cited: 2022-01-03]. DOI: 10.20364/VA-19.05. https://www.versorgungsatlas.de/fileadmin/ziva_docs/102/VA_19-05_Bericht_Depressionen_2_2019-06-27.pdf.
• Jacobi F, Klose M, Wittchen HU. Psychische Störungen in der deutschen Allgemeinbevölkerung: Inanspruchnahme von Gesundheitsleistungen und Ausfalltage. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2004; 47(8):736–44. http://www.ncbi.nlm.nih.gov/pubmed/15340716.
• Hankin BL, Abramson LY, Moffitt TE, et al. Development of depression from preadolescence to young adulthood: Emerging gender differences in a 10-year longitudinal study. J Abnorm Psychol 1998; 107(1):128–40. http://www.ncbi.nlm.nih.gov/pubmed/9505045.
• Teresi J, Abrams R, Holmes D, et al. Prevalence of depression and depression recognition in nursing homes. Soc Psychiatry Psychiatr Epidemiol. 2001; 36(12):613–20. DOI: 10.1007/s127-001-8202-7. http://www.ncbi.nlm.nih.gov/pubmed/11838834.
• Meltzer H, Gill B, Petticrew M, et al. The prevalence of psychiatric morbidity among adults living in private households (OPCS surveys of psychiatric morbidity in Great Britain). London: Palgrave Macmillan; 1995.
• Jacobi F, Höfler M, Siegert J, et al. Twelve-month prevalence, comorbidity and correlates of mental disorders in Germany: The Mental Health Module of the German Health Interview and Examination Survey for Adults (DEGS1-MH). Int J Methods Psychiatr Res 2014; 23(3):304–19. DOI: 10.1002/mpr.1439. http://www.ncbi.nlm.nih.gov/pubmed/24729411.
• Davidson JR, Meltzer-Brody SE. The underrecognition and undertreatment of depression: What is the breadth and depth of the problem? J Clin Psychiatry 1999; 60(Suppl 7):4–9. http://www.ncbi.nlm.nih.gov/pubmed/0010326869.
• Institute for Health Metrics Evaluation. GBD Results Tool. Depressive disorders. 2019 [cited: 2022-01-04]. http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/d780dffbe8a381b25e1416884959e88b.
• GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053):1545–602. DOI: 10.1016/S0140-6736(16)31678-6. http://www.ncbi.nlm.nih.gov/pubmed/27733282.
• GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053):1603–58. DOI: 10.1016/S0140-6736(16)31460-X. http://www.ncbi.nlm.nih.gov/pubmed/27733283.
• GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 2022; 9(2):137-150. DOI: 10.1016/S2215-0366(21)00395-3. http://www.ncbi.nlm.nih.gov/pubmed/35026139.
• Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: A meta-review. World Psychiatry 2014; 13(2):153–60. DOI: 10.1002/wps.20128. http://www.ncbi.nlm.nih.gov/pubmed/24890068.
• Laursen TM, Musliner KL, Benros ME, et al. Mortality and life expectancy in persons with severe unipolar depression. J Affect Disord 2016; 193:203–7. DOI: 10.1016/j.jad.2015.12.067. http://www.ncbi.nlm.nih.gov/pubmed/26773921.
• Penninx BW, Milaneschi Y, Lamers F, et al. Understanding the somatic consequences of depression: Biological mechanisms and the role of depression symptom profile. BMC Med 2013; 11:129. DOI: 10.1186/1741-7015-11-129. http://www.ncbi.nlm.nih.gov/pubmed/23672628.
• Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft Interdisziplinäre Notfall- und Akutmedizin (DGINA), Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI). S2k-Leitlinie Notfallpsychiatrie: Registernummer 038-023, Version 2019-05_01. 2019 [cited: 2021-10-28]. https://www.awmf.org/leitlinien/detail/ll/038-023.html.
• Cambridge OR, Knight MJ, Mills N, et al. The clinical relationship between cognitive impairment and psychosocial functioning in major depressive disorder: A systematic review. Psychiatry Res 2018; 269:157–71. DOI: 10.1016/j.psychres.2018.08.033. http://www.ncbi.nlm.nih.gov/pubmed/30149273.
• Ramchandani P, Stein A. The impact of parental psychiatric disorder on children. BMJ 2003; 327(7409):242–3. http://www.ncbi.nlm.nih.gov/pubmed/12896914.
• Goodman SH, Rouse MH, Connell AM, et al. Maternal depression and child psychopathology: A meta-analytic review. Clin Child Fam Psychol Rev 2011; 14(1):1–27. DOI: 10.1007/s10567-010-0080-1. http://www.ncbi.nlm.nih.gov/pubmed/21052833.
• Sweeney S, MacBeth A. The effects of paternal depression on child and adolescent outcomes: A systematic review. J Affect Disord 2016; 205:44–59. DOI: 10.1016/j.jad.2016.05.073. http://www.ncbi.nlm.nih.gov/pubmed/27414953.
• Goodman SH. Intergenerational Transmission of Depression. Annu Rev Clin Psychol 2020; 16:213–38. DOI: 10.1146/annurev-clinpsy-071519-113915. http://www.ncbi.nlm.nih.gov/pubmed/31961725.
• Knieps F, Pfaff H, editors. Psychische Gesundheit und Arbeit: Zahlen, Daten, Fakten. Berlin: Med. Wiss. Verl.-Ges.; 2019 (BKK-Gesundheitsreport; 2019).
• Storm A, editor. DAK-Gesundheitsreport 2019: Analyse der Arbeitsunfähigkeitsdaten Alte und neue Süchte im Betrieb. Heidelberg: medhochzwei Verl.; 2019 (Beiträge zur Gesundheitsökonomie und Versorgungsforschung; 28).
• Techniker Krankenkasse. Gesund­heits­re­port Arbeits­un­fä­hig­keiten 2019. 2019 [cited: 2022-01-03]. https://www.tk.de/resource/blob/2060908/b719879a6b6ca54c1f2ec600985fb616/gesundheitsreport-au-2019-data.pdf.
• Statistisches Bundesamt (Destatis). Statistisches Jahrbuch 2019 - Kapitel 4 Gesundheit. 2019 [cited: 2022-01-03]. https://www.destatis.de/DE/Themen/Querschnitt/Jahrbuch/jb-gesundheit.pdf.
• Eden J-L, Konnopka A, König H-H. Kosten der Depression in Deutschland. Psychiatr Prax 2021; 48(6):290–300. DOI: 10.1055/a-1399-4430. http://www.ncbi.nlm.nih.gov/pubmed/33773504.
• Statistisches Bundesamt (Destatis). Verlorene Erwerbstätigkeitsjahre in 1.000 Jahren für Deutschland. 2008 [cited: 2022-01-04]. https://www.gbe-bund.de/gbe.
• Statistisches Bundesamt (Destatis). Rentenzugänge wegen verminderter Erwerbsfähigkeit in der Gesetzlichen Rentenversicherung im Laufe des Berichtsjahres 2015. 2015 [cited: 2022-01-04]. https://www.gbe-bund.de/gbe.
• Statistisches Bundesamt (Destatis). Durchschnittliches Zugangsalter bei Renten wegen verminderter Erwerbsfähigkeit in der Gesetzlichen Rentenversicherung. 2015 [cited: 2022-01-04]. https://www.gbe-bund.de/gbe.
• Sartorius N. The economic and social burden of depression. J Clin Psychiatry 2001; 62(15 Suppl):8–11. http://www.ncbi.nlm.nih.gov/pubmed/11444765.
• Angermeyer MC, Matschinger H, Schomerus G. Attitudes towards psychiatric treatment and people with mental illness: Changes over two decades. Br J Psychiatry 2013; 203(2):146–51. DOI: 10.1192/bjp.bp.112.122978. http://www.ncbi.nlm.nih.gov/pubmed/23787060.
• Berger M, van Calker D, Brakemeier EL, et al. Affektive Störungen. In: Berger M, editor. Psychische Erkrankungen: Klinik und Therapie in Zusammenarbeit mit der Cochrane Deutschland Stiftung. 6th. Edinburgh: Elsevier; 2019, p. 363–435.
• Köhler CA, Evangelou E, Stubbs B, et al. Mapping risk factors for depression across the lifespan: An umbrella review of evidence from meta-analyses and Mendelian randomization studies. J Psychiatr Res 2018; 103:189–207. DOI: 10.1016/j.jpsychires.2018.05.020. http://www.ncbi.nlm.nih.gov/pubmed/29886003.
• Kennis M, Gerritsen L, van Dalen M, et al. Prospective biomarkers of major depressive disorder: A systematic review and meta-analysis. Mol Psychiatry 2020; 25(2):321–38. DOI: 10.1038/s41380-019-0585-z. http://www.ncbi.nlm.nih.gov/pubmed/31745238.
• Geschwind DH, Flint J. Genetics and genomics of psychiatric disease. Science 2015; 349(6255):1489–94. DOI: 10.1126/science.aaa8954. http://www.ncbi.nlm.nih.gov/pubmed/26404826.
• Mitchell BL, Thorp JG, Wu Y, et al. Polygenic Risk Scores Derived From Varying Definitions of Depression and Risk of Depression. JAMA Psychiatry 2021; 78(10):1152–60. DOI: 10.1001/jamapsychiatry.2021.1988. http://www.ncbi.nlm.nih.gov/pubmed/34379077.
• Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003; 301(5631):386–9. DOI: 10.1126/science.1083968. http://www.ncbi.nlm.nih.gov/pubmed/12869766.
• Border R, Johnson EC, Evans LM, et al. No Support for Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression Across Multiple Large Samples. Am J Psychiatry 2019; 176(5):376–87. DOI: 10.1176/appi.ajp.2018.18070881. http://www.ncbi.nlm.nih.gov/pubmed/30845820.
• Whiteford HA, Harris MG, McKeon G, et al. Estimating remission from untreated major depression: A systematic review and meta-analysis. Psychol Med 2013; 43(8):1569–85. DOI: 10.1017/S0033291712001717. http://www.ncbi.nlm.nih.gov/pubmed/22883473.
• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289(23):3095–105. http://www.ncbi.nlm.nih.gov/pubmed/12813115.
• Keller MB. The long-term treatment of depression. J Clin Psychiatry 1999; 60(17 Suppl):41–5. http://www.ncbi.nlm.nih.gov/pubmed/10446742.
• Keller MB, Klerman GL, Lavori PW, et al. Long-term outcome of episodes of major depression. Clinical and public health significance. JAMA 1984; 252(6):788–92. http://www.ncbi.nlm.nih.gov/pubmed/6748178.
• Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992; 49(10):809–16. http://www.ncbi.nlm.nih.gov/pubmed/1417434.
• Spijker J, Graaf R de, Bijl RV, et al. Duration of major depressive episodes in the general population: Results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002; 181:208–13. http://www.ncbi.nlm.nih.gov/pubmed/12204924.
• Schramm E, Klein DN, Elsaesser M, et al. Review of dysthymia and persistent depressive disorder: History, correlates, and clinical implications. Lancet Psychiatry 2020; 7(9):801–12. DOI: 10.1016/S2215-0366(20)30099-7. http://www.ncbi.nlm.nih.gov/pubmed/32828168.
• Murphy JA, Byrne GJ. Prevalence and correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder. J Affect Disord 2012; 139(2):172–80. DOI: 10.1016/j.jad.2012.01.033. http://www.ncbi.nlm.nih.gov/pubmed/22381955.
• Wittchen HU. Die Studie "Depression 2000". Eine bundesweite Depressions-Screening-Studie in Allgemeinarztpraxen. Fortschr Med 2000(Sonderheft I):1–3.
• Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991; 52 Suppl:28–34. http://www.ncbi.nlm.nih.gov/pubmed/1903134.
• Murray CJ, Lopez AD, editors. The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard: Harvard Univ. Pr; 1997.
• Olfson M, Shea S, Feder A, et al. Prevalence of anxiety, depression, and substance use disorders in an urban general medicine practice. Arch Fam Med 2000; 9(9):876–83. http://www.ncbi.nlm.nih.gov/pubmed/11031395.
• Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157(2):229–33. DOI: 10.1176/appi.ajp.157.2.229. http://www.ncbi.nlm.nih.gov/pubmed/10671391.
• Angst J. The course of affective disorders. Psychopathology 1986; 19 Suppl 2:47–52. http://www.ncbi.nlm.nih.gov/pubmed/3575628.
• Belsher G, Costello CG. Relapse after recovery from unipolar depression: A critical review. Psychol Bull 1988; 104(1):84–96. http://www.ncbi.nlm.nih.gov/pubmed/3043528.
• Hautzinger M, Jong-Meyer R. Zwei Multizenter-Studien zur Wirksamkeit vonVerhaltenstherapie, Pharmakotherapie und deren Kombination bei depressiven Patienten: Einführung, Rahmenbedingungen und Aufgabenstellung. Z Klin Psych 1996; 25(2):83–92.
• Hollon SD, DeRubeis RJ, Evans MD, et al. Cognitive therapy and pharmacotherapy for depression. Singly and in combination. Arch Gen Psychiatry 1992; 49(10):774–81. http://www.ncbi.nlm.nih.gov/pubmed/1417429.
• Moriarty AS, Meader N, Snell KI, et al. Prognostic models for predicting relapse or recurrence of major depressive disorder in adults. Cochrane Database Syst Rev 2021; 5:CD013491. DOI: 10.1002/14651858.CD013491.pub2. http://www.ncbi.nlm.nih.gov/pubmed/33956992.
• Buckman JE, Underwood A, Clarke K, et al. Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis. Clin Psychol Rev 2018; 64:13–38. DOI: 10.1016/j.cpr.2018.07.005. http://www.ncbi.nlm.nih.gov/pubmed/30075313.
• Wojnarowski C, Firth N, Finegan M, et al. Predictors of depression relapse and recurrence after cognitive behavioural therapy: A systematic review and meta-analysis. Behav Cogn Psychother 2019; 47(5):514–29. DOI: 10.1017/S1352465819000080. http://www.ncbi.nlm.nih.gov/pubmed/30894231.
• Steinert C, Hofmann M, Kruse J, et al. The prospective long-term course of adult depression in general practice and the community. A systematic literature review. J Affect Disord 2014; 152-154:65–75. DOI: 10.1016/j.jad.2013.10.017. http://www.ncbi.nlm.nih.gov/pubmed/24210624.
• Kautzky A, Dold M, Bartova L, et al. Clinical factors predicting treatment resistant depression: Affirmative results from the European multicenter study. Acta Psychiatr Scand 2019; 139(1):78–88. DOI: 10.1111/acps.12959. http://www.ncbi.nlm.nih.gov/pubmed/30291625.
• Perlman K, Benrimoh D, Israel S, et al. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. J Affect Disord 2019; 243:503–15. DOI: 10.1016/j.jad.2018.09.067. http://www.ncbi.nlm.nih.gov/pubmed/30286415.
• Taylor RW, Marwood L, Greer B, et al. Predictors of response to augmentation treatment in patients with treatment-resistant depression: A systematic review. J Psychopharmacol (Oxford) 2019; 33(11):1323–39. DOI: 10.1177/0269881119872194. http://www.ncbi.nlm.nih.gov/pubmed/31526204.
• Carlo V de, Calati R, Serretti A. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review. Psychiatry Res 2016; 240:421–30. DOI: 10.1016/j.psychres.2016.04.034. http://www.ncbi.nlm.nih.gov/pubmed/27155594.
• Bennabi D, Aouizerate B, El-Hage W, et al. Risk factors for treatment resistance in unipolar depression: A systematic review. J Affect Disord 2015; 171:137–41. DOI: 10.1016/j.jad.2014.09.020. http://www.ncbi.nlm.nih.gov/pubmed/25305428.
• Struijs SY, Jong PJ de, Jeronimus BF, et al. Psychological risk factors and the course of depression and anxiety disorders: A review of 15 years NESDA research. J Affect Disord 2021; 295:1347–59. DOI: 10.1016/j.jad.2021.08.086. http://www.ncbi.nlm.nih.gov/pubmed/34706448.
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Screening auf Depression – Abschlussbericht. Auftrag: S16-05. Version: 1.0. 2020 (IQWiG-Berichte; 653) [cited: 2021-11-16]. https://www.iqwig.de/download/s16-05_screening-auf-depression_abschlussbericht_v1-0.pdf.
• Whooley MA, Avins AL, Miranda J, et al. Case-finding instruments for depression. Two questions are as good as many. J Gen. Intern Med 1997; 12(7):439–45. http://www.ncbi.nlm.nih.gov/pubmed/9229283.
• Dilling H, Mombour W, Schmidt MH, et al., editors. Internationale Klassifikationen psychischer Störungen: ICD–10 Kapitel V (F) diagnostische Kriterien für Forschung und Praxis. 6th ed. Göttingen: Hogrefe; 2016.
• Kühner C, Schricker IF, Nayman S. Depressive Störungen in der ICD-11: Was bleibt, was ist neu? Psychotherapeutenjournal 2021(4):330–8. https://www.psychotherapeutenjournal.de/blaetterkatalog/PTJ-4-2021_neu/24/index.html.
• World Health Organization (WHO). ICD-11 for Mortality and Morbidity Statistics (ICD-11 MMS): International Classification of Diseases 11th Revision. The global standard for diagnostic health information. 2021 [cited: 2021-11-12]. https://icd.who.int/browse11/l-m/en.
• Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Bipolare Störungen (DGBS). S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen: Registernummer 038-019, Version 2020-05. 2020 [cited: 2021-11-09]. https://www.awmf.org/leitlinien/detail/ll/038-019.html.
• Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Burnout. 2012 [cited: 2022-01-21]. https://www.psychotherapeutenkammer-berlin.de/system/files/stellungnahme_dgppn_2012.pdf.
• Burisch M. Das Burnout-Syndrom: Theorie der inneren Erschöpfung - zahlreiche Fallbeispiele - Hilfen zur Selbsthilfe. 5th ed. Berlin: Springer; 2014.
• psychenet – Netz psychische Gesundheit. Burnout. 2021 [cited: 2022-01-21]. https://www.psychenet.de/images/Themen/FC-Burnout_20200120_Februar2021.pdf.
• Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen: Registernummer 038-020, Version 2019-07. 2019 [cited: 2021-11-10]. https://www.awmf.org/leitlinien/detail/ll/038-020.html.
• Buchholz A, Spies M, Brütt AL. ICF-basierte Messinstrumente zur Bedarfserfassung und Evaluation in der Behandlung von Patienten mit psychischen Störungen - ein systematisches Review. Rehabilitation (Stuttg) 2015; 54(3):153–9. DOI: 10.1055/s-0035-1548897. http://www.ncbi.nlm.nih.gov/pubmed/26091492.
• Blades CA, Stritzke WG, Page AC, et al. The benefits and risks of asking research participants about suicide: A meta-analysis of the impact of exposure to suicide-related content. Clin Psychol Rev 2018; 64:1–12. DOI: 10.1016/j.cpr.2018.07.001. http://www.ncbi.nlm.nih.gov/pubmed/30014862.
• DeCou CR, Schumann ME. On the Iatrogenic Risk of Assessing Suicidality: A Meta-Analysis. Suicide Life Threat Behav 2018; 48(5):531–43. DOI: 10.1111/sltb.12368. http://www.ncbi.nlm.nih.gov/pubmed/28678380.
• Dube P, Kurt K, Bair MJ, et al. The p4 screener: Evaluation of a brief measure for assessing potential suicide risk in 2 randomized effectiveness trials of primary care and oncology patients. Prim Care Companion J Clin Psychiatry 2010; 12(6). DOI: 10.4088/PCC.10m00978blu. http://www.ncbi.nlm.nih.gov/pubmed/21494337.
• Schlüssel S. Evaluation of the P4 suicidality screener in primary and specialized care in Germany [in Erstellung].
• Löwe B, Spitzer RL, Zipfel S, et al. PHQ-D - Gesundheitsfragebogen für Patienten. Karlsruhe: Pfizer; 2001.
• Löwe B, Spitzer RL, Gräfe K, et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians' diagnoses. J Affect. Disord 2004; 78(2):131–40. http://www.ncbi.nlm.nih.gov/pubmed/14706723.
• Elwyn G, Vermunt NP. Goal-Based Shared Decision-Making: Developing an Integrated Model. Journal of Patient Experience 2020; 7(5):688-696. DOI: 10.1177/2374373519878604. http://www.ncbi.nlm.nih.gov/pubmed/33294602.
• Deutsches Netzwerk Evidenzbasierte Medizin (DNEbM). Gute Praxis Gesundheitsinformation. Ein Positionspapier des Deutschen Netzwerks Evidenzbasierte Medizin. Version 2.0. Stand: 18.10.2015. 2015 [cited: 2017-10-17]. http://www.ebm-netzwerk.de/pdf/publikationen/gpgi2.pdf.
• Linde K, Kriston L, Rücker G, et al. Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: Systematic review and network meta-analysis. Ann Fam Med 2015; 13(1):69–79. DOI: 10.1370/afm.1687. http://www.ncbi.nlm.nih.gov/pubmed/25583895.
• Cuijpers P, Karyotaki E, Ciharova M, et al. The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis. Acta Psychiatr Scand 2021; 144(3):288-299. DOI: 10.1111/ACPS.13335. http://www.ncbi.nlm.nih.gov/pubmed/34107050.
• Samalin L, Genty J-B, Boyer L, et al. Shared Decision-Making: A Systematic Review Focusing on Mood Disorders. Curr Psychiatry Rep 2018:23. DOI: 10.1007/s11920-018-0892-0. http://www.ncbi.nlm.nih.gov/pubmed/29589129.
• Loh A, Simon D, Kriston L, et al. Patientenbeteiligung bei medizinischen Entscheidungen - Effekte der Partizipativen Entscheidungsfindung aus systematischen Reviews. Dtsch Arztebl 2007; 104(21):A-1483-8.
• LeBlanc A, Herrin J, Williams MD, et al. Shared Decision Making for Antidepressants in Primary Care: A Cluster Randomized Trial. JAMA Intern Med 2015; 175(11):1761–70. DOI: 10.1001/jamainternmed.2015.5214. http://www.ncbi.nlm.nih.gov/pubmed/26414670.
• Aljumah K, Hassali MA. Impact of pharmacist intervention on adherence and measurable patient outcomes among depressed patients: A randomised controlled study. BMC Psychiatry 2015:219. DOI: 10.1186/s12888-015-0605-8. http://www.ncbi.nlm.nih.gov/pubmed/26376830.
• Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017; 4(4):CD001431. DOI: 10.1002/14651858.CD001431.pub5. http://www.ncbi.nlm.nih.gov/pubmed/28402085.
• Tlach L, Wüsten C, Daubmann A, et al. Information and decision-making needs among people with mental disorders: A systematic review of the literature. Health Expect 2015; 18(6):1856–72. DOI: 10.1111/hex.12251.
• Härter M. Partizipative Entscheidungsfindung (Shared Decision Making) - ein von Patienten, Ärzten und der Gesundheitspolitik geforderter Ansatz setzt sich durch. Z Arztl. Fortbild. Qualitatssich. 2004; 98(2):89–92. http://www.ncbi.nlm.nih.gov/pubmed/15106486.
• Elwyn G, Durand MA, Song J, et al. A three-talk model for shared decision making: Multistage consultation process. BMJ 2017; 359:j4891. DOI: 10.1136/bmj.j4891. http://www.ncbi.nlm.nih.gov/pubmed/29109079.
• Bieber C, Gschwendtner K, Müller N, et al. Partizipative Entscheidungsfindung (PEF) - Patient und Arzt als Team. Psychother Psychosom Med Psychol 2016; 66(5):195–207. DOI: 10.1055/s-0042-105277. http://www.ncbi.nlm.nih.gov/pubmed/27119359.
• Petrak F, Meier JJ, Albus C, et al. Motivation und Diabetes – Zeit für einen Paradigmenwechsel?: – Ein Positionspapier –. Diabet Stoffw 2019; 14(03):193–203. DOI: 10.1055/a-0868-7758.
• Schaub A, Roth E, Goldmann U. Kognitiv-psychoedukative Therapie zur Bewältigung von Depressionen: Ein Therapiemanual. 2nd ed. Göttingen: Hogrefe; 2013.
• Pitschel-Walz G, Bäuml J, Kissling W. Psychoedukation Depressionen: Manual zur Leitung von Patienten- und Angehörigengruppen. 2nd ed. München: Urban und Fischer; 2018.
• Köhnen M, Kriston L, Härter M, et al. Effectiveness and Acceptance of Technology-Based Psychological Interventions for the Acute Treatment of Unipolar Depression: A systematic review and meta-analysis. J Med Internet Res 2021; 23(6):e24584. DOI: 10.2196/24584. http://www.ncbi.nlm.nih.gov/pubmed/36260395.
• Wells MJ, Owen JJ, McCray LW, et al. Computer-Assisted Cognitive-Behavior Therapy for Depression in Primary Care: Systematic Review and Meta-Analysis. Prim Care Companion CNS Disord 2018; 20(2). DOI: 10.4088/PCC.17r02196. http://www.ncbi.nlm.nih.gov/pubmed/29570963.
• Königbauer J, Letsch J, Philipp D, et al. Internet- and mobile-based depression interventions for people with diagnosed depression: A systematic review and meta-analysis. J Affect Disord 2017; 223:28–40. DOI: 10.1016/j.jad.2017.07.021. http://www.ncbi.nlm.nih.gov/pubmed/28715726.
• Baumel A, Edan S, Kane JM. Is there a trial bias impacting user engagement with unguided e-mental health interventions? A systematic comparison of published reports and real-world usage of the same programs. Transl Behav Med 2019; 9(6):1020–33. DOI: 10.1093/tbm/ibz147. http://www.ncbi.nlm.nih.gov/pubmed/31689344.
• Baumeister H, Reichler L, Munzinger M, et al. The impact of guidance on Internet-based mental health interventions – A systematic review. Internet Interventions 2014; 1(4):205–15. DOI: 10.1016/j.invent.2014.08.003.
• Gold PW, Machado-Vieira R, Pavlatou MG. Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress. Neural Plast 2015; 2015:581976. DOI: 10.1155/2015/581976. http://www.ncbi.nlm.nih.gov/pubmed/25878903.
• Jakobsen JC, Katakam KK, Schou A, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry 2017; 17(1):58. DOI: 10.1186/s12888-016-1173-2. http://www.ncbi.nlm.nih.gov/pubmed/28178949.
• Hengartner MP, Jakobsen JC, Sørensen A, et al. Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials. PLoS. One. 2020; 15(2):e0229381. DOI: 10.1371/journal.pone.0229381. http://www.ncbi.nlm.nih.gov/pubmed/32101579.
• Plöderl M, Hengartner MP. Guidelines for the pharmacological acute treatment of major depression: Conflicts with current evidence as demonstrated with the German S3-guidelines. BMC Psychiatry 2019; 19(1):265. DOI: 10.1186/s12888-019-2230-4. http://www.ncbi.nlm.nih.gov/pubmed/31477074.
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet 2018; 391(10128):1357–66. DOI: 10.1016/S0140-6736(17)32802-7. http://www.ncbi.nlm.nih.gov/pubmed/29477251.
• Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis. J Affect Disord 2018; 241:484–91. DOI: 10.1016/j.jad.2018.08.056. http://www.ncbi.nlm.nih.gov/pubmed/30149336.
• Bousman CA, Arandjelovic K, Mancuso SG, et al. Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials. Pharmacogenomics 2019; 20(1):37–47. DOI: 10.2217/pgs-2018-0142. http://www.ncbi.nlm.nih.gov/pubmed/30520364.
• Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res 2019; 111:59–67. DOI: 10.1016/j.jpsychires.2019.01.003. http://www.ncbi.nlm.nih.gov/pubmed/30677646.
• Perlis RH, Dowd D, Fava M, et al. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. Depress Anxiety 2020. DOI: 10.1002/da.23029. http://www.ncbi.nlm.nih.gov/pubmed/32383277.
• Han C, Wang S-M, Bahk W-M, et al. A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial. Clin Psychopharmacol Neurosci 2018; 16(4):469–80. DOI: 10.9758/cpn.2018.16.4.469. http://www.ncbi.nlm.nih.gov/pubmed/30466219.
• Bradley P, Shiekh M, Mehra V, et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. J Psychiatr Res 2018; 96:100–7. DOI: 10.1016/j.jpsychires.2017.09.024. http://www.ncbi.nlm.nih.gov/pubmed/28992526.
• Pérez V, Salavert A, Espadaler J, et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial. BMC Psychiatry 2017; 17(1):250. DOI: 10.1186/s12888-017-1412-1. http://www.ncbi.nlm.nih.gov/pubmed/28705252.
• Singh AB. Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report. Clin Psychopharmacol Neurosci 2015; 13(2):150–6. DOI: 10.9758/cpn.2015.13.2.150. http://www.ncbi.nlm.nih.gov/pubmed/26243841.
• Winner JG, Carhart JM, Altar CA, et al. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med 2013; 16(89):219–27. http://www.ncbi.nlm.nih.gov/pubmed/24229738.
• van der Schans J, Hak E, Postma M, et al. Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial). J Clin Psychopharmacol 2019; 39(6):583–90. DOI: 10.1097/JCP.0000000000001129. http://www.ncbi.nlm.nih.gov/pubmed/31688392.
• Ruaño G, Robinson S, Holford T, et al. Results of the CYP-GUIDES randomized controlled trial: Total cohort and primary endpoints. Contemp Clin Trials 2020; 89:105910. DOI: 10.1016/j.cct.2019.105910. http://www.ncbi.nlm.nih.gov/pubmed/31838256.
• Shan X, Zhao W, Qiu Y, et al. Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study. Front Neurosci 2019; 13:960. DOI: 10.3389/fnins.2019.00960. http://www.ncbi.nlm.nih.gov/pubmed/31572113.
• Stassen HH, Angst J, Hell D, et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007; 68(8):1195–205. http://www.ncbi.nlm.nih.gov/pubmed/17854243.
• Angst J, Stassen HH. Do antidepressants really take several weeks to show effect? In: Leonard BE, editor. Antidepressants. Basel: Birkhäuser; 2001, p. 21–30.
• Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 2005; 66(2):148–58. http://www.ncbi.nlm.nih.gov/pubmed/15704999.
• Papakostas GI, Perlis RH, Scalia MJ, et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006; 26(1):56–60. http://www.ncbi.nlm.nih.gov/pubmed/16415707.
• Henssler J, Kurschus M, Franklin J, et al. Trajectories of Acute Antidepressant Efficacy: How Long to Wait for Response? A Systematic Review and Meta-Analysis of Long-Term, Placebo-Controlled Acute Treatment Trials. J Clin Psychiatry 2018; 79(3). DOI: 10.4088/JCP.17r11470. http://www.ncbi.nlm.nih.gov/pubmed/29659207.
• Wagner S, Engel A, Engelmann J, et al. Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systematic review and meta-analysis. J Psychiatr Res 2017; 94:96–106. DOI: 10.1016/j.jpsychires.2017.07.003. http://www.ncbi.nlm.nih.gov/pubmed/28697423.
• Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51(1-02):9–62. DOI: 10.1055/s-0043-116492. http://www.ncbi.nlm.nih.gov/pubmed/28910830.
• Benkert O, Hippius H, editors. Kompendium der Psychiatrischen Pharmakotherapie. 13th ed. Berlin: Springer; 2021.
• Henssler J, Heinz A, Brandt L, et al. Absetz- und Rebound-Phänomene bei Antidepressiva. Dtsch Arztebl Int 2019; 116(20):355–61. DOI: 10.3238/arztebl.2019.0355. http://www.ncbi.nlm.nih.gov/pubmed/31288917.
• van Leeuwen E, van Driel ML, Horowitz MA, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev 2021; 4:CD013495. DOI: 10.1002/14651858.CD013495.pub2. http://www.ncbi.nlm.nih.gov/pubmed/33886130.
• Gutwinski S, Fierley L, Schreiter S, et al. Entzugssyndrom nach dem Absetzen von Lithium – Eine systematische Literaturübersicht. Psychiatr Prax 2021; 48(7):341-350. DOI: 10.1055/a-1481-1953. http://www.ncbi.nlm.nih.gov/pubmed/34015856.
• Bundespsychotherapeutenkammer (BPtK). BPtK-Studie: Ein Jahr nach der Reform der Psychotherapie-Richtlinie. Wartezeiten 2018. 2018 [cited: 2022-01-12]. https://www.bptk.de/wp-content/uploads/2019/01/20180411_bptk_studie_wartezeiten_2018.pdf.
• Bundespsychotherapeutenkammer (BPtK). BPtK-Studie zu Wartezeiten in der ambulanten psychotherapeutischen Versorgung. Umfrage der Landespsychotherapeutenkammern und der BPtK. 2011 [cited: 2022-01-12]. https://www.bptk.de/wp-content/uploads/2019/01/20110622_BPtK-Studie_Langfassung_Wartezeiten-in-der-Psychotherapie.pdf.
• Sachverständigenrat Gesundheit (SVR). Digitalisierung für Gesundheit. Ziele und Rahmenbedingungen eines dynamisch lernenden Gesundheitssystems. 2021 [cited: 2022-01-12]. https://www.svr-gesundheit.de/fileadmin/Gutachten/Gutachten_2021/SVR_Gutachten_2021.pdf.
• Bundespsychotherapeutenkammer (BPtK). BPtK-Auswertung: Monatelange Wartezeiten bei Psychotherapeut*innen. 2021 [cited: 2022-01-12]. https://www.bptk.de/wp-content/uploads/2021/03/20210329_pm_bptk_monatelange-Wartezeiten.pdf.
• Gemeinsamer Bundesausschuss (G-BA). Richtlinie des Gemeinsamen Bundesausschusses über die Durchführung der Psychotherapie (Psychotherapie-Richtlinie). In der Fassung vom 19. Februar 2009 veröffentlicht im Bundesanzeiger Nr. 58 (S. 1 399) vom 17. April 2009 in Kraft getreten am 18. April 2009 zuletzt geändert am 20. November 2020 veröffentlicht im Bundesanzeiger (BAnz AT 17.02.2021 B1) in Kraft getreten am 18. Februar 2021. 2021 [cited: 2021-08-23]. https://www.g-ba.de/downloads/62-492-2400/PT-RL_2020-11-20_iK-2021-02-18.pdf.
• Del Re AC, Flückiger C, Horvath AO, et al. Examining therapist effects in the alliance-outcome relationship: A multilevel meta-analysis. J Consult Clin Psychol 2021; 89(5):371–8. DOI: 10.1037/ccp0000637. http://www.ncbi.nlm.nih.gov/pubmed/33829817.
• Flückiger C, Del Re AC, Wampold BE, et al. The alliance in adult psychotherapy: A meta-analytic synthesis. Psychotherapy (Chic) 2018; 55(4):316–40. DOI: 10.1037/pst0000172. http://www.ncbi.nlm.nih.gov/pubmed/29792475.
• Bohart AC, Greaves Wade A. The Client in Psychotherapy. In: Lambert MJ, editor. Bergin and Garfield's handbook of psychotherapy and behavior change. 6th. New York: Wiley; 2013, 219-257.
• Crits-Christoph P, Connolly Gibbons MB, Mukherjee D. Psychotherapy Process-Outcome Research. In: Lambert MJ, editor. Bergin and Garfield's handbook of psychotherapy and behavior change. 6th. New York: Wiley; 2013, p. 298–342.
• Baldwin SA, Imel ZE. Therapist Effects: Findings and Methods. In: Lambert MJ, editor. Bergin and Garfield's handbook of psychotherapy and behavior change. 6th. New York: Wiley; 2013, p. 258–297.
• Linden M, Strauß B, Scholten S, et al. Definition und Entscheidungsschritte in der Bestimmung und Erfassung von Nebenwirkungen von Psychotherapie. Psychother Psychosom Med Psychol 2018; 68(9-10):377–82. DOI: 10.1055/a-0619-5949. http://www.ncbi.nlm.nih.gov/pubmed/30286505.
• Brakemeier E-L, Jacobi F. Nebenwirkungen von Psychotherapie. In: Brakemeier E-L, Jacobi F, editors. Verhaltenstherapie in der Praxis. Weinheim: Beltz; 2017, p. 921–929.
• Ladwig I, Rief W, Nestoriuc Y. Welche Risiken und Nebenwirkungen hat Psychotherapie?: - Entwicklung des Inventars zur Erfassung Negativer Effekte von Psychotherapie (INEP). Verhaltensther 2014; 24(4):252–63. DOI: 10.1159/000367928.
• Rozental A, Kottorp A, Forsström D, et al. The Negative Effects Questionnaire: Psychometric properties of an instrument for assessing negative effects in psychological treatments. Behav Cogn Psychother 2019; 47(5):559–72. DOI: 10.1017/S1352465819000018. http://www.ncbi.nlm.nih.gov/pubmed/30871650.
• Moritz S, Nestoriuc Y, Rief W, et al. It can't hurt, right? Adverse effects of psychotherapy in patients with depression. Eur Arch Psychiatry Clin Neurosci 2019; 269(5):577–86. DOI: 10.1007/s00406-018-0931-1. http://www.ncbi.nlm.nih.gov/pubmed/30088072.
• Wampold BE, Imel ZE. The Great Psychotherapy Debate: The Evidence for What Makes Psychotherapy Work. 2nd ed. London: Routledge; 2015.
• Zhang S, Lin X, Yang T, et al. Prevalence of childhood trauma among adults with affective disorder using the Childhood Trauma Questionnaire: A meta-analysis. J Affect Disord 2020:546–54. DOI: 10.1016/j.jad.2020.07.001. http://www.ncbi.nlm.nih.gov/pubmed/32871685.
• Negele A, Kaufhold J, Kallenbach L, et al. Childhood Trauma and Its Relation to Chronic Depression in Adulthood. Depress Res Treat 2015:650804. DOI: 10.1155/2015/650804. http://www.ncbi.nlm.nih.gov/pubmed/26693349.
• Deutschsprachige Gesellschaft für Psychotraumatologie (DeGPT), Bundespsychotherapeutenkammer (BPtK), Bundesvereinigung Verhaltenstherapie im Kindes- und Jugendalter (BVKJ). S3-Leitlinie Posttraumatische Belastungsstörung: Registernummer 155-001, Version 2020-02_1. 2019 [cited: 2021-08-23]. https://www.awmf.org/leitlinien/detail/ll/155-001.html.
• Deutschsprachige Gesellschaft für Psychotraumatologie (DeGPT), Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Psychologie (DGPs). S2k-Leitlinie Diagnostik und Behandlung von akuten Folgen psychischer Traumatisierung: Registernummer 051-027, Version 2019-10. 2019 [cited: 2021-08-23]. https://www.awmf.org/leitlinien/detail/ll/051-027.html.
• Lutz W, Jong K de, Rubel J. Patient-focused and feedback research in psychotherapy: Where are we and where do we want to go? Psychother Res 2015; 25(6):625–32. DOI: 10.1080/10503307.2015.1079661. http://www.ncbi.nlm.nih.gov/pubmed/26376225.
• Lambert MJ, Lo Coco G. Simple Methods for Enhancing Patient Outcome in Routine Care: Measuring, Monitoring, and Feedback. Res Psychother 2014; 16(2):93–101. DOI: 10.7411/RP.2013.011.
• Multmeier J, Tenckhoff B. Psychotherapeutische Versorgung: Autonomere Therapieplanung kann Wartezeiten abbauen. Dtsch Arztebl 2014; 111(11):A 438–40.
• Matzat J. Selbsthilfegruppen. In: Köhle K, Herzog W, Joraschky P, Kruse J, Langewitz W, Söllner W, editors. Psychosomatische Medizin: Theoretische Modelle und klinische Praxis. 8th. München: Urban und Fischer; 2017, p. 569–574.
• Tursi MF, Baes Cv, Camacho FR, et al. Effectiveness of psychoeducation for depression: A systematic review. Aust N Z J Psychiatry 2013; 47(11):1019–31. DOI: 10.1177/0004867413491154. http://www.ncbi.nlm.nih.gov/pubmed/23739312.
• Linde K, Sigterman K, Kriston L, et al. Effectiveness of psychological treatments for depressive disorders in primary care: Systematic review and meta-analysis. Ann Fam Med 2015; 13(1):56–68. DOI: 10.1370/afm.1719. http://www.ncbi.nlm.nih.gov/pubmed/25583894.
• Linde K, Rücker G, Sigterman K, et al. Comparative effectiveness of psychological treatments for depressive disorders in primary care: Network meta-analysis. BMC Fam Pract 2015; 16:103. DOI: 10.1186/s12875-015-0314-x. http://www.ncbi.nlm.nih.gov/pubmed/26286590.
• Grünzig S-D, Bengel J, Göhner W, et al. Low-Intensity Interventions to Reduce Depressive Symptoms before Outpatient Psychotherapy - A Systematic Literature Review. Psychother Psychosom Med Psychol 2019; 69(6):212–23. DOI: 10.1055/a-0630-2397. http://www.ncbi.nlm.nih.gov/pubmed/30045413.
• Uphoff E, Ekers D, Robertson L, et al. Behavioural activation therapy for depression in adults. Cochrane Database Syst Rev 2020; 7:CD013305. DOI: 10.1002/14651858.CD013305.pub2. http://www.ncbi.nlm.nih.gov/pubmed/32628293.
• Seshadri A, Orth SS, Adaji A, et al. Mindfulness-Based Cognitive Therapy, Acceptance and Commitment Therapy, and Positive Psychotherapy for Major Depression. Am J Psychother 2020:appipsychotherapy20200006. DOI: 10.1176/appi.psychotherapy.20200006. http://www.ncbi.nlm.nih.gov/pubmed/32985916.
• Iglesias-González M, Aznar-Lou I, Gil-Girbau M, et al. Comparing watchful waiting with antidepressants for the management of subclinical depression symptoms to mild-moderate depression in primary care: A systematic review. Fam Pract 2017; 34(6):639–48. DOI: 10.1093/fampra/cmx054. http://www.ncbi.nlm.nih.gov/pubmed/28985309.
• Stein AT, Carl E, Cuijpers P, et al. Looking beyond depression: A meta-analysis of the effect of behavioral activation on depression, anxiety, and activation. Psychol Med 2020:1–14. DOI: 10.1017/S0033291720000239. http://www.ncbi.nlm.nih.gov/pubmed/32138802.
• Gualano MR, Bert F, Martorana M, et al. The long-term effects of bibliotherapy in depression treatment: Systematic review of randomized clinical trials. Clin Psychol Rev 2017; 58:49–58. DOI: 10.1016/j.cpr.2017.09.006. http://www.ncbi.nlm.nih.gov/pubmed/28993103.
• Santoft F, Axelsson E, Öst L-G, et al. Cognitive behaviour therapy for depression in primary care: Systematic review and meta-analysis. Psychol Med 2019; 49(8):1266–74. DOI: 10.1017/S0033291718004208. http://www.ncbi.nlm.nih.gov/pubmed/30688184.
• Zhang A, Borhneimer LA, Weaver A, et al. Cognitive behavioral therapy for primary care depression and anxiety: A secondary meta-analytic review using robust variance estimation in meta-regression. J Behav Med 2019; 42(6):1117–41. DOI: 10.1007/s10865-019-00046-z. http://www.ncbi.nlm.nih.gov/pubmed/31004323.
• Chi X, Bo A, Liu T, et al. Effects of Mindfulness-Based Stress Reduction on Depression in Adolescents and Young Adults: A Systematic Review and Meta-Analysis. Front Psychol 2018; 9:1034. DOI: 10.3389/fpsyg.2018.01034. http://www.ncbi.nlm.nih.gov/pubmed/29977221.
• Thimm JC, Johnsen TJ. Time trends in the effects of mindfulness-based cognitive therapy for depression: A meta-analysis. Scand J Psychol 2020; 61(4):582–91. DOI: 10.1111/sjop.12642. http://www.ncbi.nlm.nih.gov/pubmed/32319124.
• Cuijpers P, Wit Ld, Kleiboer A, et al. Problem-solving therapy for adult depression: An updated meta-analysis. Eur Psychiatry 2018; 48:27–37. DOI: 10.1016/j.eurpsy.2017.11.006. http://www.ncbi.nlm.nih.gov/pubmed/29331596.
• Shang P, Cao X, You S, et al. Problem-solving therapy for major depressive disorders in older adults: An updated systematic review and meta-analysis of randomized controlled trials. Aging Clin Exp Res 2020. DOI: 10.1007/s40520-020-01672-3. http://www.ncbi.nlm.nih.gov/pubmed/32767273.
• Karyotaki E, Kemmeren L, Riper H, et al. Is self-guided internet-based cognitive behavioural therapy (iCBT) harmful? An individual participant data meta-analysis. Psychol Med 2018; 48(15):2456–66. DOI: 10.1017/S0033291718000648. http://www.ncbi.nlm.nih.gov/pubmed/29540243.
• Carlbring P, Andersson G, Cuijpers P, et al. Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: An updated systematic review and meta-analysis. Cogn Behav Ther 2018; 47(1):1–18. DOI: 10.1080/16506073.2017.1401115. http://www.ncbi.nlm.nih.gov/pubmed/29215315.
• Etzelmueller A, Vis C, Karyotaki E, et al. Effects of Internet-Based Cognitive Behavioral Therapy in Routine Care for Adults in Treatment for Depression and Anxiety: Systematic Review and Meta-Analysis. J Med Internet Res 2020; 22(8):e18100. DOI: 10.2196/18100. http://www.ncbi.nlm.nih.gov/pubmed/32865497.
• Pabst A, Löbner M, Stein J, et al. Internet-Based Cognitive Behavior Therapy Only for the Young? A Secondary Analysis of a Randomized Controlled Trial of Depression Treatment. Front Psychiatry 2020; 11:735. DOI: 10.3389/fpsyt.2020.00735. http://www.ncbi.nlm.nih.gov/pubmed/32848915.
• Gloaguen V, Cottraux J, Cucherat M, et al. A meta-analysis of the effects of cognitive therapy in depressed patients. J Affect. Disord 1998; 49(1):59–72. DOI: 10.1016/s0165-0327(97)00199-7. http://www.ncbi.nlm.nih.gov/pubmed/9574861.
• Dobson KS. A meta-analysis of the efficacy of cognitive therapy for depression. J Consult Clin Psychol 1989; 57(3):414–9. http://www.ncbi.nlm.nih.gov/pubmed/2738214.
• Gaffan EA, Tsaousis I, Kemp-Wheeler SM. Researcher allegiance and meta-analysis: The case of cognitive therapy for depression. J Consult Clin Psychol 1995; 63(6):966–80. http://www.ncbi.nlm.nih.gov/pubmed/8543719.
• Leichsenring F. Comparative effects of short-term psychodynamic psychotherapy and cognitive-behavioral therapy in depression: A meta-analytic approach. Clin Psychol Rev 2001; 21(3):401–19. http://www.ncbi.nlm.nih.gov/pubmed/11288607.
• Leichsenring F. Are psychodynamic and psychoanalytic therapies effective?: A review of empirical data. Int J Psychoanal. 2005; 86(Pt 3):841–68. http://www.ncbi.nlm.nih.gov/pubmed/16096078.
• Barth J, Munder T, Gerger H, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: A network meta-analysis. PLoS Med 2013; 10(5):e1001454. DOI: 10.1371/journal.pmed.1001454. http://www.ncbi.nlm.nih.gov/pubmed/23723742.
• Feijo de Mello M, Jesus Mari J de, Bacaltchuk J, et al. A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders. Eur Arch Psychiatry Clin Neurosci 2004; 255(2):75.
• Driessen E, Cuijpers P, Maat SC de, et al. The efficacy of short-term psychodynamic psychotherapy for depression: A meta-analysis. Clin Psychol Rev 2010; 30(1):25–36. DOI: 10.1016/j.cpr.2009.08.010. http://www.ncbi.nlm.nih.gov/pubmed/19766369.
• Cuijpers P, Clignet F, van Meijel B, et al. Psychological treatment of depression in inpatients: A systematic review and meta-analysis. Clin Psychol Rev 2011; 31(3):353–60. DOI: 10.1016/j.cpr.2011.01.002. http://www.ncbi.nlm.nih.gov/pubmed/21382540.
• Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of psychotherapy for adult depression are overestimated: A meta-analysis of study quality and effect size. Psychol Med 2010; 40(2):211–23. DOI: 10.1017/S0033291709006114. http://www.ncbi.nlm.nih.gov/pubmed/19490745.
• Toseland RW, Siporin M. When to recommend group treatment: A review of the clinical and the research literature. Int J Group Psychother 1986; 36(2):171–201. http://www.ncbi.nlm.nih.gov/pubmed/3733290.
• Vander-Voort DJ, Fuhriman A. The efficacy of group therapy for depression. Small Group Res 1991; 22:320–38.
• McDermut W, Miller IW, Brown RA. The Efficacy of Group Psychotherapy for Depression: A Meta-Analysis and Review of the Empirical Research. Clin Psychol Sci Prac 2001; 8:98–116.
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Systemische Therapie bei Erwachsenen als Psychotherapieverfahren. Abschlussbericht. Auftrag N14-02. Version: 1.0. 2017 (IQWiG-Berichte; 513) [cited: 2019-07-25]. https://www.iqwig.de/download/N14-02_Abschlussbericht_Systemische-Therapie-bei-Erwachsenen_V1-0.pdf.
• Abbass AA, Kisely SR, Town JM, et al. Short-term psychodynamic psychotherapies for common mental disorders. Cochrane Database Syst Rev 2014(7):CD004687. DOI: 10.1002/14651858.CD004687.pub4. http://www.ncbi.nlm.nih.gov/pubmed/24984083.
• Shinohara K, Honyashiki M, Imai H, et al. Behavioural therapies versus other psychological therapies for depression. Cochrane Database Syst Rev 2013(10):CD008696. DOI: 10.1002/14651858.CD008696.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24129886.
• Churchill R, Moore TH, Furukawa TA, et al. 'Third wave' cognitive and behavioural therapies versus treatment as usual for depression. Cochrane Database Syst Rev 2013(10):CD008705. DOI: 10.1002/14651858.CD008705.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24142810.
• Hunot V, Moore TH, Caldwell DM, et al. 'Third wave' cognitive and behavioural therapies versus other psychological therapies for depression. Cochrane Database Syst Rev 2013(10):CD008704. DOI: 10.1002/14651858.CD008704.pub2. http://www.ncbi.nlm.nih.gov/pubmed/24142844.
• Barbato A, D'Avanzo B, Parabiaghi A. Couple therapy for depression. Cochrane Database Syst Rev 2018; 6(6):CD004188. DOI: 10.1002/14651858.CD004188.pub3. http://www.ncbi.nlm.nih.gov/pubmed/29882960.
• National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. Consultation draft. 2018 (NICE Guideline) [cited: 2019-07-25]. https://www.nice.org.uk/guidance/gid-cgwave0725/documents/full-guideline-updated.
• Cuijpers P, Karyotaki E, Reijnders M, et al. Was Eysenck right after all? A reassessment of the effects of psychotherapy for adult depression. Epidemiol Psychiatr Sci 2019; 28(1):21–30. DOI: 10.1017/S2045796018000057. http://www.ncbi.nlm.nih.gov/pubmed/29486804.
• Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysis. Ann Fam Med 2005; 3(5):449–56. http://www.ncbi.nlm.nih.gov/pubmed/16189062.
• Storosum JG, Elferink AJ, van Zwieten BJ, et al. Short-term efficacy of tricyclic antidepressants revisited: A meta-analytic study. Eur Neuropsychopharmacol 2001; 11(2):173–80. http://www.ncbi.nlm.nih.gov/pubmed/11313164.
• Macgillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: Systematic review and meta-analysis. BMJ 2003; 326(7397):1014. http://www.ncbi.nlm.nih.gov/pubmed/12742924.
• Bech P, Cialdella P, Haugh MC, et al. Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000; 176:421–8. http://www.ncbi.nlm.nih.gov/pubmed/10912216.
• Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999; 20(3):226–47. http://www.ncbi.nlm.nih.gov/pubmed/10063483.
• Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: Meta-analysis and prospective studies. J Clin Psychopharmacol. 1995; 15(4 Suppl 2):16S-23S. http://www.ncbi.nlm.nih.gov/pubmed/7593725.
• Mulrow CD, Williams JW, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000; 108(1):54–64. http://www.ncbi.nlm.nih.gov/pubmed/11059441.
• Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS. Med 2008; 5(2):e45. DOI: 10.1371/journal.pmed.0050045. http://www.ncbi.nlm.nih.gov/pubmed/18303940.
• Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 2002; 287(14):1840–7. http://www.ncbi.nlm.nih.gov/pubmed/11939870.
• Stolk P, Berg MJ ten, Hemels ME, et al. Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother 2003; 37(12):1891–9. http://www.ncbi.nlm.nih.gov/pubmed/14632596.
• Khan A, Leventhal RM, Khan SR, et al. Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22(1):40–5. http://www.ncbi.nlm.nih.gov/pubmed/11799341.
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet 2009; 373(9665):746–58. http://www.ncbi.nlm.nih.gov/pubmed/19185342.
• Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA 2010; 303(1):47–53. DOI: 10.1001/jama.2009.1943. http://www.ncbi.nlm.nih.gov/pubmed/20051569.
• Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: Synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69(6):572–9. DOI: 10.1001/archgenpsychiatry.2011.2044. http://www.ncbi.nlm.nih.gov/pubmed/22393205.
• Furukawa TA, Maruo K, Noma H, et al. Initial severity of major depression and efficacy of new generation antidepressants: Individual participant data meta-analysis. Acta Psychiatr Scand 2018; 137(6):450–8. DOI: 10.1111/acps.12886. http://www.ncbi.nlm.nih.gov/pubmed/29611870.
• Agency for Healthcare Research and Quality (AHRQ). Nonpharmacological Versus Pharmacological Treatments for Adult Patients With Major Depressive Disorder. 2015 (Comparative Effectiveness Review; 161) [cited: 2019-07-24]. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/major-depressive-disorder_research.pdf.
• Weitz ES, Hollon SD, Twisk J, et al. Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis. JAMA Psychiatry 2015; 72(11):1102–9. DOI: 10.1001/jamapsychiatry.2015.1516. http://www.ncbi.nlm.nih.gov/pubmed/26397232.
• Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry 2020; 19(1):92–107. DOI: 10.1002/wps.20701. http://www.ncbi.nlm.nih.gov/pubmed/31922679.
• Furukawa TA, Weitz ES, Tanaka S, et al. Initial severity of depression and efficacy of cognitive-behavioural therapy: Individual-participant data meta-analysis of pill-placebo-controlled trials. Br J Psychiatry 2017; 210(3):190–6. DOI: 10.1192/bjp.bp.116.187773. http://www.ncbi.nlm.nih.gov/pubmed/28104735.
• Cuijpers P, Hollon SD, van Straten A, et al. Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. BMJ Open 2013; 3(4). DOI: 10.1136/bmjopen-2012-002542. http://www.ncbi.nlm.nih.gov/pubmed/23624992.
• Boschloo L, Bekhuis E, Weitz ES, et al. The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: Results from an individual patient data meta-analysis. World Psychiatry 2019; 18(2):183–91. DOI: 10.1002/wps.20630. http://www.ncbi.nlm.nih.gov/pubmed/31059603.
• Vittengl JR, Jarrett RB, Weitz E, et al. Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. Am J Psychiatry 2016; 173(5):481–90. DOI: 10.1176/appi.ajp.2015.15040492. http://www.ncbi.nlm.nih.gov/pubmed/26869246.
• Bares M, Novak T, Brunovsky M, et al. The Comparison of Effectiveness of Various Potential Predictors of Response to Treatment With SSRIs in Patients With Depressive Disorder. J Nerv Ment Dis 2017; 205(8):618–26. DOI: 10.1097/NMD.0000000000000574. http://www.ncbi.nlm.nih.gov/pubmed/27660994.
• Berryhill MB, Culmer N, Williams N, et al. Videoconferencing Psychotherapy and Depression: A Systematic Review. Telemed J E Health 2019; 25(6):435–46. DOI: 10.1089/tmj.2018.0058. http://www.ncbi.nlm.nih.gov/pubmed/30048211.
• Bundesärztekammer (BÄK). Handreichung für Ärztinnen und Ärzte zur Umsetzung von Videosprechstunden in der Praxis. Dtsch Arztebl 2020; 117(40):A-1882.
• Bundespsychotherapeutenkammer (BPtK). Videobehandlung. Praxis-Info. 2021 [cited: 2022-05-30]. https://www.bptk.de/wp-content/uploads/2020/03/bptk_praxisInfo_videobehandlung_21_web.pdf.
• Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008(4):CD000448. http://www.ncbi.nlm.nih.gov/pubmed/18843608.
• Haller H, Anheyer D, Cramer H, et al. Complementary therapies for clinical depression: An overview of systematic reviews. BMJ Open 2019; 9(8):e028527. DOI: 10.1136/bmjopen-2018-028527. http://www.ncbi.nlm.nih.gov/pubmed/31383703.
• Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John's wort for major depressive disorder. Syst Rev 2016; 5(1):148. DOI: 10.1186/s13643-016-0325-2. http://www.ncbi.nlm.nih.gov/pubmed/27589952.
• Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM). Nicht erholsamer Schlaf/Schlafstörungen, Kapitel „Insomnie bei Erwachsenen“. Version 2.0. S3-Leitlinie. 2017 [cited: 2018-06-29]. http://www.awmf.org/uploads/tx_szleitlinien/063-003l_S3_Insomnie-Erwachsene_2018-02.pdf.
• Driessen E, Dekker JJ, Peen J, et al. The efficacy of adding short-term psychodynamic psychotherapy to antidepressants in the treatment of depression: A systematic review and meta-analysis of individual participant data. Clin Psychol Rev 2020; 80:101886. DOI: 10.1016/j.cpr.2020.101886. http://www.ncbi.nlm.nih.gov/pubmed/32650213.
• Berger T, Krieger T, Sude K, et al. Evaluating an e-mental health program ("deprexis") as adjunctive treatment tool in psychotherapy for depression: Results of a pragmatic randomized controlled trial. J Affect Disord 2018; 227:455–62. DOI: 10.1016/j.jad.2017.11.021. http://www.ncbi.nlm.nih.gov/pubmed/29154168.
• Zwerenz R, Becker J, Knickenberg RJ, et al. Online Self-Help as an Add-On to Inpatient Psychotherapy: Efficacy of a New Blended Treatment Approach. Psychother. Psychosom. 2017; 86(6):341–50. DOI: 10.1159/000481177. http://www.ncbi.nlm.nih.gov/pubmed/29131090.
• Zwerenz R, Baumgarten C, Becker J, et al. Improving the Course of Depressive Symptoms After Inpatient Psychotherapy Using Adjunct Web-Based Self-Help: Follow-Up Results of a Randomized Controlled Trial. J Med Internet Res 2019; 21(10):e13655. DOI: 10.2196/13655. http://www.ncbi.nlm.nih.gov/pubmed/31651403.
• Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: A systematic review. Arch Gen Psychiatry 2004; 61(7):714–9. http://www.ncbi.nlm.nih.gov/pubmed/15237083.
• Khan A, Brodhead AE, Kolts RL, et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005; 39(2):145–50. DOI: 10.1016/j.jpsychires.2004.06.005. http://www.ncbi.nlm.nih.gov/pubmed/15589562.
• Ogawa Y, Takeshima N, Hayasaka Y, et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev 2019; 6(6):CD001026. DOI: 10.1002/14651858.CD001026.pub2. http://www.ncbi.nlm.nih.gov/pubmed/31158298.
• Benasi G, Guidi J, Offidani E, et al. Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review. Psychother Psychosom 2018; 87(2):65–74. DOI: 10.1159/000486696. http://www.ncbi.nlm.nih.gov/pubmed/29466801.
• Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht). S3-Leitlinie Medikamentenbezogene Störungen. Langfassung: Registernummer 038-025, Version 1.1. 2021 [cited: 2022-07-07]. https://www.awmf.org/leitlinien/detail/ll/038-025.html.
• Wijkstra J, Lijmer J, Burger H, et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2015(7):CD004044. DOI: 10.1002/14651858.CD004044.pub4. http://www.ncbi.nlm.nih.gov/pubmed/26225902.
• Kruizinga J, Liemburg E, Burger H, et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2021(12):1203. DOI: 10.1002/14651858.CD004044.pub5.
• Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 2012; 73(4):486–96. DOI: 10.4088/JCP.11r07324. http://www.ncbi.nlm.nih.gov/pubmed/22579147.
• Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. Lancet 2003; 361(9358):653–61. http://www.ncbi.nlm.nih.gov/pubmed/12606176.
• Machmutow K, Meister R, Jansen A, et al. Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults. Cochrane Database Syst Rev 2019; 5(5):CD012855. DOI: 10.1002/14651858.CD012855.pub2. http://www.ncbi.nlm.nih.gov/pubmed/31106850.
• Sim K, Lau WK, Sim J, et al. Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials. Int J Neuropsychopharmacol 2015; 19(2). DOI: 10.1093/ijnp/pyv076. http://www.ncbi.nlm.nih.gov/pubmed/26152228.
• Flint AJ, Meyers BS, Rothschild AJ, et al. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. JAMA 2019; 322(7):622–31. DOI: 10.1001/jama.2019.10517. http://www.ncbi.nlm.nih.gov/pubmed/31429896.
• Clarke K, Mayo-Wilson E, Kenny J, et al. Can non-pharmacological interventions prevent relapse in adults who have recovered from depression? A systematic review and meta-analysis of randomised controlled trials. Clin Psychol Rev 2015; 39:58–70. DOI: 10.1016/j.cpr.2015.04.002. http://www.ncbi.nlm.nih.gov/pubmed/25939032.
• Vittengl JR, Clark LA, Dunn TW, et al. Reducing relapse and recurrence in unipolar depression: A comparative meta-analysis of cognitive-behavioral therapy's effects. J Consult Clin Psychol 2007; 75(3):475–88. http://www.ncbi.nlm.nih.gov/pubmed/17563164.
• Galante J, Iribarren SJ, Pearce PF. Effects of mindfulness-based cognitive therapy on mental disorders: A systematic review and meta-analysis of randomised controlled trials. J Res Nurs 2013; 18(2):133–55. DOI: 10.1177/1744987112466087. http://www.ncbi.nlm.nih.gov/pubmed/27660642.
• Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: A systematic review and meta-analysis. Clin Psychol Rev 2011; 31(6):1032–40. DOI: 10.1016/j.cpr.2011.05.002. http://www.ncbi.nlm.nih.gov/pubmed/21802618.
• Cuijpers P, Geraedts AS, van Oppen P, et al. Interpersonal psychotherapy for depression: A meta-analysis. Am J Psychiatry 2011; 168(6):581–92. DOI: 10.1176/appi.ajp.2010.10101411. http://www.ncbi.nlm.nih.gov/pubmed/21362740.
• Guidi J, Fava GA. Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry 2021; 78(3):261–9. DOI: 10.1001/jamapsychiatry.2020.3650. http://www.ncbi.nlm.nih.gov/pubmed/33237285.
• Breedvelt JJ, Brouwer ME, Harrer M, et al. Psychological interventions as an alternative and add-on to antidepressant medication to prevent depressive relapse: Systematic review and meta-analysis. Br J Psychiatry 2020:1–8. DOI: 10.1192/bjp.2020.198. http://www.ncbi.nlm.nih.gov/pubmed/33205715.
• DeRubeis RJ, Zajecka J, Shelton RC, et al. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry 2020; 77(3):237–45. DOI: 10.1001/jamapsychiatry.2019.3900. http://www.ncbi.nlm.nih.gov/pubmed/31799993.
• Jong-Meyer R de, Hautzinger M, Kühner C, et al. Evidenzbasierte Leitlinie zur Psychotherapie Affektiver Störungen. Göttingen: Hogrefe; 2007 (Evidenzbasierte Leitlinien Psychotherapie; 1).
• Rush AJ, Aaronson ST, Demyttenaere K. Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry 2019; 53(2):109–18. DOI: 10.1177/0004867418808585. http://www.ncbi.nlm.nih.gov/pubmed/30378447.
• McPherson S, Cairns P, Carlyle J, et al. The effectiveness of psychological treatments for treatment-resistant depression: A systematic review. Acta Psychiatr Scand 2005; 111(5):331–40. http://www.ncbi.nlm.nih.gov/pubmed/15819726.
• Trivedi RB, Nieuwsma JA, Williams JW. Examination of the utility of psychotherapy for patients with treatment resistant depression: A systematic review. J Gen Intern Med 2011; 26(6):643–50. DOI: 10.1007/s11606-010-1608-2. http://www.ncbi.nlm.nih.gov/pubmed/21184287.
• Ijaz S, Davies P, Williams CJ, et al. Psychological therapies for treatment-resistant depression in adults. Cochrane Database Syst Rev 2018; 5(5):CD010558. DOI: 10.1002/14651858.CD010558.pub2. http://www.ncbi.nlm.nih.gov/pubmed/29761488.
• Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013; 10(3):e1001403. DOI: 10.1371/journal.pmed.1001403. http://www.ncbi.nlm.nih.gov/pubmed/23554581.
• Komossa K, Depping AM, Gaudchau A, et al. Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010(12):CD008121. DOI: 10.1002/14651858.CD008121.pub2. http://www.ncbi.nlm.nih.gov/pubmed/21154393.
• Edwards SJ, Hamilton V, Nherera L, et al. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: A systematic review and economic evaluation. Health Technol Assess 2013; 17(54):1–190. DOI: 10.3310/hta17540. http://www.ncbi.nlm.nih.gov/pubmed/24284258.
• Davies P, Ijaz S, Williams CJ, et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev 2019; 12:CD010557. DOI: 10.1002/14651858.CD010557.pub2. http://www.ncbi.nlm.nih.gov/pubmed/31846068.
• Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 2006; 12(23):2985–92. http://www.ncbi.nlm.nih.gov/pubmed/16918427.
• Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19(5):427–34. http://www.ncbi.nlm.nih.gov/pubmed/10505584.
• Bauer M, Adli M, Baethge C, et al. Lithium augmentation therapy in refractory depression: Clinical evidence and neurobiological mechanisms. Can J Psychiatry 2003; 48(7):440–8. http://www.ncbi.nlm.nih.gov/pubmed/12971013.
• Nelson JC, Baumann P, Delucchi K, et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014; 168:269–75. DOI: 10.1016/j.jad.2014.05.053. http://www.ncbi.nlm.nih.gov/pubmed/25069082.
• McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: A systematic review and meta-analysis. Lancet 2012; 379(9817):721–8. DOI: 10.1016/S0140-6736(11)61516-X. http://www.ncbi.nlm.nih.gov/pubmed/22265699.
• Bauer M, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157(9):1429–35. http://www.ncbi.nlm.nih.gov/pubmed/10964859.
• Bschor T, Berghöfer A, Ströhle A, et al. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol. 2002; 22(4):427–30. DOI: 10.1097/00004714-200208000-00016. http://www.ncbi.nlm.nih.gov/pubmed/12172345.
• McIntyre RS, Lee Y, Zhou AJ, et al. The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol 2017; 37(4):412–8. DOI: 10.1097/JCP.0000000000000723. http://www.ncbi.nlm.nih.gov/pubmed/28590365.
• Kleeblatt J, Betzler F, Kilarski LL, et al. Efficacy of off-label augmentation in unipolar depression: A systematic review of the evidence. Eur Neuropsychopharmacol 2017; 27(5):423–41. DOI: 10.1016/j.euroneuro.2017.03.003. http://www.ncbi.nlm.nih.gov/pubmed/28318897.
• Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: Systematic review and network meta-analysis. J Clin Psychiatry 2015; 76(4):e487-98. DOI: 10.4088/JCP.14r09204. http://www.ncbi.nlm.nih.gov/pubmed/25919841.
• Köberle U. Augmentation mit Schilddrüsenhormonen. In: Bschor T, editor. Behandlungsmanual therapieresistente Depression: Pharmakotherapie ; somatische Therapieverfahren ; Psychotherapie. Stuttgart: Kohlhammer; 2008, p. 129–141.
• Prange AJ Jr, Wilson IC, Breese GR, Lipton MA. Hormonal alteration of imipramine response: A review. In: Sachar EJ, editor. Hormones, behavior, and psychopathology. New York: Raven Press; 1976, p. 41–51.
• Lopes Rocha F, Fuzikawa C, Riera R, et al. Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis. J Clin Psychopharmacol 2012; 32(2):278–81. DOI: 10.1097/JCP.0b013e318248581b. http://www.ncbi.nlm.nih.gov/pubmed/22367652.
• Lopes Rocha F, Fuzikawa C, Riera R, et al. Antidepressant combination for major depression in incomplete responders--a systematic review. J Affect Disord 2013; 144(1-2):1–6. DOI: 10.1016/j.jad.2012.04.048. http://www.ncbi.nlm.nih.gov/pubmed/22835845.
• Henssler J, Bschor T, Baethge C. Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 Patients. Can J Psychiatry 2016; 61(1):29–43. DOI: 10.1177/0706743715620411. http://www.ncbi.nlm.nih.gov/pubmed/27582451.
• Bschor T, Baethge C. No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 2010; 121(3):174–9. DOI: 10.1111/j.1600-0447.2009.01458.x. http://www.ncbi.nlm.nih.gov/pubmed/19703121.
• Bschor T, Kern H, Henssler J, et al. Switching the Antidepressant After Nonresponse in Adults With Major Depression: A Systematic Literature Search and Meta-Analysis. J Clin Psychiatry 2018; 79(1). DOI: 10.4088/JCP.16r10749. http://www.ncbi.nlm.nih.gov/pubmed/27929611.
• Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255(6):387–400. http://www.ncbi.nlm.nih.gov/pubmed/15868067.
• Jakubovski E, Varigonda AL, Freemantle N, et al. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. Am J Psychiatry 2016; 173(2):174–83. DOI: 10.1176/appi.ajp.2015.15030331. http://www.ncbi.nlm.nih.gov/pubmed/26552940.
• Rink L, Braun C, Bschor T, et al. Dose Increase Versus Unchanged Continuation of Antidepressants After Initial Antidepressant Treatment Failure in Patients With Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized, Double-Blind Trials. J Clin Psychiatry 2018; 79(3). DOI: 10.4088/JCP.17r11693. http://www.ncbi.nlm.nih.gov/pubmed/29873954.
• Braun C, Adams A, Rink L, et al. In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis. Acta Psychiatr Scand 2020; 142(6):430–42. DOI: 10.1111/acps.13235. http://www.ncbi.nlm.nih.gov/pubmed/32970827.
• Rink L, Adams A, Braun C, et al. Dose-Response Relationship in Selective Serotonin and Norepinephrine Reuptake Inhibitors in the Treatment of Major Depressive Disorder: A Meta-Analysis and Network Meta-Analysis of Randomized Controlled Trials. Psychother Psychosom 2021:1–10. DOI: 10.1159/000520554. http://www.ncbi.nlm.nih.gov/pubmed/34965534.
• Ricken R, Ulrich S, Schlattmann P, et al. Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol 2017; 27(8):714–31. DOI: 10.1016/j.euroneuro.2017.04.003. http://www.ncbi.nlm.nih.gov/pubmed/28579071.
• Baethge C, Braun C, Rink L, et al. Dose effects of tricyclic antidepressants in the treatment of acute depression - A systematic review and meta-analysis of randomized trials. J Affect Disord 2022; 307:191–8. DOI: 10.1016/j.jad.2022.03.075. http://www.ncbi.nlm.nih.gov/pubmed/35390353.
• Maneeton B, Maneeton N, Woottiluk P, et al. Repetitive Transcranial Magnetic Stimulation Combined with Antidepressants for the First Episode of Major Depressive Disorder. Curr Neuropharmacol 2020; 18(9):852–60. DOI: 10.2174/1570159X18666200221113134. http://www.ncbi.nlm.nih.gov/pubmed/32091338.
• Voigt J, Carpenter L, Leuchter A. A systematic literature review of the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) in non-treatment resistant patients with major depressive disorder. BMC Psychiatry 2019; 19(1):13. DOI: 10.1186/s12888-018-1989-z. http://www.ncbi.nlm.nih.gov/pubmed/30621636.
• Mutz J, Vipulananthan V, Carter B, et al. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: Systematic review and network meta-analysis. BMJ 2019; 364:l1079. DOI: 10.1136/bmj.l1079. http://www.ncbi.nlm.nih.gov/pubmed/30917990.
• Zis P, Shafique F, Hadjivassiliou M, et al. Safety, Tolerability, and Nocebo Phenomena During Transcranial Magnetic Stimulation: A Systematic Review and Meta-Analysis of Placebo-Controlled Clinical Trials. Neuromodulation 2020; 23(3):291–300. DOI: 10.1111/ner.12946. http://www.ncbi.nlm.nih.gov/pubmed/30896060.
• Lambert MJ, Bergin AE, Garfield SL, editors. Bergin and Garfield's handbook of psychotherapy and behavior change. 7th ed. New York: Wiley; 2021.
• Cuijpers P, Huibers M, Ebert DD, et al. How much psychotherapy is needed to treat depression? A metaregression analysis. J Affect Disord 2013; 149(1-3):1–13. DOI: 10.1016/j.jad.2013.02.030. http://www.ncbi.nlm.nih.gov/pubmed/23528438.
• Bruijniks SJ, Lemmens LH, Hollon SD, et al. The effects of once- versus twice-weekly sessions on psychotherapy outcomes in depressed patients. Br J Psychiatry 2020; 216(4):222–30. DOI: 10.1192/bjp.2019.265. http://www.ncbi.nlm.nih.gov/pubmed/32029012.
• Israel JA. The Impact of Residual Symptoms in Major Depression. Pharmaceuticals (Basel) 2010; 3(8):2426–40. DOI: 10.3390/ph3082426. http://www.ncbi.nlm.nih.gov/pubmed/27713362.
• Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol 2019; 22(10):616–30. DOI: 10.1093/ijnp/pyz039. http://www.ncbi.nlm.nih.gov/pubmed/31290965.
• Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry 2019; 176(6):428–38. DOI: 10.1176/appi.ajp.2019.19020172. http://www.ncbi.nlm.nih.gov/pubmed/31109201.
• Ochs-Ross R, Daly EJ, Zhang Y, et al. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. Am J Geriatr Psychiatry 2020; 28(2):121–41. DOI: 10.1016/j.jagp.2019.10.008. http://www.ncbi.nlm.nih.gov/pubmed/31734084.
• Fu D-J, Ionescu DF, Li X, et al. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J Clin Psychiatry 2020; 81(3):19m13191. DOI: 10.4088/JCP.19m13191. http://www.ncbi.nlm.nih.gov/pubmed/32412700.
• Ionescu DF, Fu D-J, Qiu X, et al. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients with Major Depressive Disorder Who Have Active Suicide Ideation with Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol 2020:pyaa068. DOI: 10.1093/ijnp/pyaa068. http://www.ncbi.nlm.nih.gov/pubmed/32861217.
• Daly EJ, Trivedi MH, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2019; 76(9):893–903. DOI: 10.1001/jamapsychiatry.2019.1189. http://www.ncbi.nlm.nih.gov/pubmed/31166571.
• Caddy C, Amit BH, McCloud TL, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev 2015(9):CD011612. DOI: 10.1002/14651858.CD011612.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26395901.
• Doherty T, Wajs E, Melkote R, et al. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program. CNS Drugs 2020; 34(3):299–310. DOI: 10.1007/s40263-020-00699-4. http://www.ncbi.nlm.nih.gov/pubmed/31994024.
• Su T-P, Chen M-H, Li C-T, et al. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. Neuropsychopharmacology 2017; 42(13):2482–92. DOI: 10.1038/npp.2017.94. http://www.ncbi.nlm.nih.gov/pubmed/28492279.
• Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry 2020; 25(7):1592–603. DOI: 10.1038/s41380-018-0256-5. http://www.ncbi.nlm.nih.gov/pubmed/30283029.
• Grunebaum MF, Galfalvy HC, Choo T-H, et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry 2018; 175(4):327–35. DOI: 10.1176/appi.ajp.2017.17060647. http://www.ncbi.nlm.nih.gov/pubmed/29202655.
• Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry 2016; 173(8):816–26. DOI: 10.1176/appi.ajp.2016.16010037. http://www.ncbi.nlm.nih.gov/pubmed/27056608.
• The UK ECT review group. Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. Lancet 2003; 361(9360):799–808. http://www.ncbi.nlm.nih.gov/pubmed/12642045.
• Pagnin D, Queiroz V de, Pini S, et al. Efficacy of ECT in depression: A meta-analytic review. J ECT. 2004; 20(1):13–20. http://www.ncbi.nlm.nih.gov/pubmed/15087991.
• Brandon S, Cowley P, McDonald C, et al. Electroconvulsive therapy: Results in depressive illness from the Leicestershire trial. Br Med J (Clin Res Ed) 1984; 288(6410):22–5. DOI: 10.1136/bmj.288.6410.22. http://www.ncbi.nlm.nih.gov/pubmed/6418300.
• Pluijms EM, Kamperman AM, Hoogendijk WJ, et al. Influence of an adjuvant antidepressant on the efficacy of electroconvulsive therapy: A systematic review and meta-analysis. Aust N Z J Psychiatry 2021; 55(4):366–80. DOI: 10.1177/0004867420952543. http://www.ncbi.nlm.nih.gov/pubmed/32900217.
• van Diermen L, van den Ameele S, Kamperman AM, et al. Prediction of electroconvulsive therapy response and remission in major depression: Meta-analysis. Br J Psychiatry 2018; 212(2):71–80. DOI: 10.1192/bjp.2017.28. http://www.ncbi.nlm.nih.gov/pubmed/29436330.
• Dong M, Zhu X-M, Zheng W, et al. Electroconvulsive therapy for older adult patients with major depressive disorder: A systematic review of randomized controlled trials. Psychogeriatrics 2018; 18(6):468–75. DOI: 10.1111/psyg.12359. http://www.ncbi.nlm.nih.gov/pubmed/30073725.
• Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: A review of 50 years' experience. Am J Psychiatry 1994; 151(2):169–76. DOI: 10.1176/ajp.151.2.169. http://www.ncbi.nlm.nih.gov/pubmed/8296883.
• Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: A systematic review and meta-analysis. Biol Psychiatry 2010; 68(6):568–77. DOI: 10.1016/j.biopsych.2010.06.009. http://www.ncbi.nlm.nih.gov/pubmed/20673880.
• Lisanby SH, Maddox JH, Prudic J, et al. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry 2000; 57(6):581–90. http://www.ncbi.nlm.nih.gov/pubmed/10839336.
• Devanand DP, Fitzsimons L, Prudic J, et al. Subjective side effects during electroconvulsive therapy. Convuls Ther 1995; 11(4):232–40. http://www.ncbi.nlm.nih.gov/pubmed/8919573.
• Vann Jones S, McCollum R. Subjective memory complaints after electroconvulsive therapy: Systematic review. BJPsych Bull 2019; 43(2):73–80. DOI: 10.1192/bjb.2018.45. http://www.ncbi.nlm.nih.gov/pubmed/30860456.
• Semkovska M, Knittle H, Leahy J, et al. Subjective cognitive complaints and subjective cognition following electroconvulsive therapy for depression: A systematic review and meta-analysis. Aust N Z J Psychiatry 2022; 57(1):21-33. DOI: 10.1177/00048674221089231. http://www.ncbi.nlm.nih.gov/pubmed/35362328.
• Li X-M, Shi Z-M, Wang P-J, et al. Effects of ketamine in electroconvulsive therapy for major depressive disorder: Meta-analysis of randomised controlled trials. Gen Psychiatr 2020; 33(3):e100117. DOI: 10.1136/gpsych-2019-100117. http://www.ncbi.nlm.nih.gov/pubmed/32596639.
• Zheng W, Li X-H, Zhu X-M, et al. Adjunctive ketamine and electroconvulsive therapy for major depressive disorder: A meta-analysis of randomized controlled trials. J Affect Disord 2019; 250:123–31. DOI: 10.1016/j.jad.2019.02.044. http://www.ncbi.nlm.nih.gov/pubmed/30852364.
• Stripp TK, Jorgensen MB, Olsen NV. Anaesthesia for electroconvulsive therapy - new tricks for old drugs: A systematic review. Acta Neuropsychiatr 2018; 30(2):61–9. DOI: 10.1017/neu.2017.12. http://www.ncbi.nlm.nih.gov/pubmed/28462732.
• Cobb K, Nanda M. Ketamine and electroconvulsive therapy: So happy together? Curr Opin Anaesthesiol 2018; 31(4):459–62. DOI: 10.1097/ACO.0000000000000607. http://www.ncbi.nlm.nih.gov/pubmed/29794567.
• Jelovac A, Kolshus E, McLoughlin DM. Relapse following successful electroconvulsive therapy for major depression: A meta-analysis. Neuropsychopharmacology 2013; 38(12):2467–74. DOI: 10.1038/npp.2013.149. http://www.ncbi.nlm.nih.gov/pubmed/23774532.
• Petrides G, Tobias KG, Kellner CH, et al. Continuation and maintenance electroconvulsive therapy for mood disorders: Review of the literature. Neuropsychobiology 2011; 64(3):129–40. DOI: 10.1159/000328943. http://www.ncbi.nlm.nih.gov/pubmed/21811083.
• Brown ED, Lee H, Scott D, et al. Efficacy of continuation/maintenance electroconvulsive therapy for the prevention of recurrence of a major depressive episode in adults with unipolar depression: A systematic review. J ECT 2014; 30(3):195–202. DOI: 10.1097/YCT.0000000000000085. http://www.ncbi.nlm.nih.gov/pubmed/24979654.
• Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: A multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006; 63(12):1337–44. http://www.ncbi.nlm.nih.gov/pubmed/17146008.
• Elias A, Phutane VH, Clarke S, et al. Electroconvulsive therapy in the continuation and maintenance treatment of depression: Systematic review and meta-analyses. Aust N Z J Psychiatry 2018; 52(5):415–24. DOI: 10.1177/0004867417743343. http://www.ncbi.nlm.nih.gov/pubmed/29256252.
• Mutz J, Edgcumbe DR, Brunoni AR, et al. Efficacy and acceptability of non-invasive brain stimulation for the treatment of adult unipolar and bipolar depression: A systematic review and meta-analysis of randomised sham-controlled trials. Neurosci Biobehav Rev 2018; 92:291–303. DOI: 10.1016/j.neubiorev.2018.05.015. http://www.ncbi.nlm.nih.gov/pubmed/29763711.
• Razza LB, Moffa AH, Moreno ML, et al. A systematic review and meta-analysis on placebo response to repetitive transcranial magnetic stimulation for depression trials. Prog Neuro-Psychopharmacol Biol Psychiatry 2018; 81:105–13. DOI: 10.1016/j.pnpbp.2017.10.016. http://www.ncbi.nlm.nih.gov/pubmed/29111404.
• Chen J-J, Zhao L-B, Liu Y-Y, et al. Comparative efficacy and acceptability of electroconvulsive therapy versus repetitive transcranial magnetic stimulation for major depression: A systematic review and multiple-treatments meta-analysis. Behav Brain Res 2017; 320:30–6. DOI: 10.1016/j.bbr.2016.11.028. http://www.ncbi.nlm.nih.gov/pubmed/27876667.
• Senova S, Cotovio G, Pascual-Leone A, et al. Durability of antidepressant response to repetitive transcranial magnetic stimulation: Systematic review and meta-analysis. Brain Stimul 2019; 12(1):119–28. DOI: 10.1016/j.brs.2018.10.001. http://www.ncbi.nlm.nih.gov/pubmed/30344109.
• Razza LB, Palumbo P, Moffa AH, et al. A systematic review and meta-analysis on the effects of transcranial direct current stimulation in depressive episodes. Depress Anxiety 2020; 37(7):594–608. DOI: 10.1002/da.23004. http://www.ncbi.nlm.nih.gov/pubmed/32101631.
• Smet S de, Nikolin S, Moffa A, et al. Determinants of sham response in tDCS depression trials: A systematic review and meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry 2021; 109:110261. DOI: 10.1016/j.pnpbp.2021.110261. http://www.ncbi.nlm.nih.gov/pubmed/33497753.
• Park S, Choi W-J, Kim S, et al. Effects of transcranial direct current stimulation using miniaturized devices vs sertraline for depression in Korea: A 6 week, multicenter, randomized, double blind, active-controlled study. J Psychiatr Res 2020; 127:42–7. DOI: 10.1016/j.jpsychires.2020.04.012. http://www.ncbi.nlm.nih.gov/pubmed/32464489.
• Brunoni AR, Moffa AH, Sampaio-Junior B, et al. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. N Engl J Med 2017; 376(26):2523–33. DOI: 10.1056/NEJMoa1612999. http://www.ncbi.nlm.nih.gov/pubmed/28657871.
• Bottomley JM, LeReun C, Diamantopoulos A, et al. Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: A systematic review and meta-analysis. Compr Psychiatry 2019; 98:152156. DOI: 10.1016/j.comppsych.2019.152156. http://www.ncbi.nlm.nih.gov/pubmed/31978785.
• Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: A naturalistic study. Biol. Psychiatry 2005; 58(5):355–63. http://www.ncbi.nlm.nih.gov/pubmed/16139581.
• Aaronson ST, Carpenter LL, Conway CR, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: Acute and chronic effects. Brain Stimul 2013; 6(4):631–40. DOI: 10.1016/j.brs.2012.09.013. http://www.ncbi.nlm.nih.gov/pubmed/23122916.
• Aaronson ST, Sears P, Ruvuna F, et al. A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality. Am J Psychiatry 2017; 174(7):640–8. DOI: 10.1176/appi.ajp.2017.16010034. http://www.ncbi.nlm.nih.gov/pubmed/28359201.
• Hitti FL, Yang AI, Cristancho MA, et al. Deep Brain Stimulation Is Effective for Treatment-Resistant Depression: A Meta-Analysis and Meta-Regression. J Clin Med 2020; 9(9). DOI: 10.3390/jcm9092796. http://www.ncbi.nlm.nih.gov/pubmed/32872572.
• Julião ÍE, Santana DF, Silva LJ. Deep Brain Stimulation for the Treatment of Resistant Depression: Systematic Review of the Literature. Arq Bras Neurocir 2019; 38(03):183–98. DOI: 10.1055/s-0039-1692158. https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0039-1692158.
• Jiang J, Zhang C, Li C, et al. Magnetic seizure therapy for treatment-resistant depression. Cochrane Database Syst Rev 2021; 6:CD013528. DOI: 10.1002/14651858.CD013528.pub2. http://www.ncbi.nlm.nih.gov/pubmed/34131914.
• Price L, Briley J, Haltiwanger S, et al. A meta-analysis of cranial electrotherapy stimulation in the treatment of depression. J Psychiatr Res 2021; 135:119–34. DOI: 10.1016/j.jpsychires.2020.12.043. http://www.ncbi.nlm.nih.gov/pubmed/33477056.
• Cuijpers P, van Straten A, Schuurmans J, et al. Psychotherapy for chronic major depression and dysthymia: A meta-analysis. Clin Psychol Rev 2010; 30(1):51–62. DOI: 10.1016/j.cpr.2009.09.003. http://www.ncbi.nlm.nih.gov/pubmed/19781837.
• Wolff A von, Hölzel LP, Westphal A, et al. Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: A systematic review and meta-analysis. BMC Psychiatry 2012; 12:61. DOI: 10.1186/1471-244X-12-61. http://www.ncbi.nlm.nih.gov/pubmed/22694751.
• Wolff A von, Hölzel LP, Westphal A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: A systematic review and meta-analysis. J Affect Disord 2013; 144(1-2):7–15. DOI: 10.1016/j.jad.2012.06.007. http://www.ncbi.nlm.nih.gov/pubmed/22963896.
• Negt P, Brakemeier E-L, Michalak J, et al. The treatment of chronic depression with cognitive behavioral analysis system of psychotherapy: A systematic review and meta-analysis of randomized-controlled clinical trials. Brain Behav 2016; 6(8):e00486. DOI: 10.1002/brb3.486. http://www.ncbi.nlm.nih.gov/pubmed/27247856.
• Furukawa TA, Efthimiou O, Weitz ES, et al. Cognitive-Behavioral Analysis System of Psychotherapy, Drug, or Their Combination for Persistent Depressive Disorder: Personalizing the Treatment Choice Using Individual Participant Data Network Metaregression. Psychother Psychosom 2018; 87(3):140–53. DOI: 10.1159/000489227. http://www.ncbi.nlm.nih.gov/pubmed/29847831.
• Silva de Lima M, Moncrieff J, Soares BG. WITHDRAWN: Drugs versus placebo for dysthymia. Cochrane Database Syst Rev 2015(6):CD001130. DOI: 10.1002/14651858.CD001130.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26087170.
• Kriston L, Wolff A von, Westphal A, et al. Efficacy and acceptability of acute treatments for persistent depressive disorder: A network meta-analysis. Depress Anxiety 2014; 31(8):621–30. DOI: 10.1002/da.22236. http://www.ncbi.nlm.nih.gov/pubmed/24448972.
• Pjrek E, Friedrich M-E, Cambioli L, et al. The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials. Psychother Psychosom 2020; 89(1):17–24. DOI: 10.1159/000502891. http://www.ncbi.nlm.nih.gov/pubmed/31574513.
• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Herbst-Winter-Depression. Führen nicht medikamentöse Verfahren wie Licht- und Vitamintherapie zu besseren Ergebnissen? Vorläufiger HTA-Bericht. HTA-Nummer: HT18-04. Version 1.0. 2020 [cited: 2020-01-23]. https://www.themencheck-medizin.iqwig.de/media/download/ae12f719-9bfb-4fcf-949a-bdaa89725849.
• Nussbaumer-Streit B, Forneris CA, Morgan LC, et al. Light therapy for preventing seasonal affective disorder. Cochrane Database Syst Rev 2019; 3(3):CD011269. DOI: 10.1002/14651858.CD011269.pub3. http://www.ncbi.nlm.nih.gov/pubmed/30883670.
• Tao L, Jiang R, Zhang K, et al. Light therapy in non-seasonal depression: An update meta-analysis. Psychiatry Res 2020; 291:113247. DOI: 10.1016/j.psychres.2020.113247. http://www.ncbi.nlm.nih.gov/pubmed/32622169.
• Zhao X, Ma J, Wu S, et al. Light therapy for older patients with non-seasonal depression: A systematic review and meta-analysis. J Affect Disord 2018; 232:291–9. DOI: 10.1016/j.jad.2018.02.041. http://www.ncbi.nlm.nih.gov/pubmed/29500957.
• Chang C-H, Liu C-Y, Chen S-J, et al. Efficacy of light therapy on nonseasonal depression among elderly adults: A systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018; 14:3091–102. DOI: 10.2147/NDT.S180321. http://www.ncbi.nlm.nih.gov/pubmed/30532540.
• Geoffroy PA, Schroder CM, Reynaud E, et al. Efficacy of light therapy versus antidepressant drugs, and of the combination versus monotherapy, in major depressive episodes: A systematic review and meta-analysis. Sleep Med Rev 2019; 48:101213. DOI: 10.1016/j.smrv.2019.101213. http://www.ncbi.nlm.nih.gov/pubmed/31600678.
• Brouwer A, Nguyen H-T, Snoek FJ, et al. Light therapy: Is it safe for the eyes? Acta psychiatrica Scandinavica 2017; 136(6):534–48. DOI: 10.1111/acps.12785. http://www.ncbi.nlm.nih.gov/pubmed/28891192.
• Leibenluft E, Wehr TA. Is sleep deprivation useful in the treatment of depression? Am J Psychiatry 1992; 149(2):159–68. http://www.ncbi.nlm.nih.gov/pubmed/1734735.
• Kuhs H, Tolle R. Sleep deprivation therapy. Biol. Psychiatry 1991; 29(11):1129–48. http://www.ncbi.nlm.nih.gov/pubmed/1873374.
• Ioannou M, Wartenberg C, Greenbrook JT, et al. Sleep deprivation as treatment for depression: Systematic review and meta-analysis. Acta Psychiatr Scand 2021; 143(1):22–35. DOI: 10.1111/acps.13253. http://www.ncbi.nlm.nih.gov/pubmed/33145770.
• Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev 2013(9):CD004366. DOI: 10.1002/14651858.CD004366.pub6. http://www.ncbi.nlm.nih.gov/pubmed/24026850.
• Blake H, Mo P, Malik S, et al. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. Clin Rehabil 2009; 23(10):873–87. DOI: 10.1177/0269215509337449. http://www.ncbi.nlm.nih.gov/pubmed/19675114.
• Bridle C, Spanjers K, Patel S, et al. Effect of exercise on depression severity in older people: Systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2012; 201(3):180–5. DOI: 10.1192/bjp.bp.111.095174. http://www.ncbi.nlm.nih.gov/pubmed/22945926.
• Potter R, Ellard D, Rees K, et al. A systematic review of the effects of physical activity on physical functioning, quality of life and depression in older people with dementia. Int J Geriatr Psychiatry 2011; 26(10):1000–11. DOI: 10.1002/gps.2641. http://www.ncbi.nlm.nih.gov/pubmed/21905096.
• Robertson R, Robertson A, Jepson R, et al. Walking for depression or depressive symptoms: A systematic review and meta-analysis. Mental Health and Physical Activity 2012; 5(1):66–75. DOI: 10.1016/j.mhpa.2012.03.002.
• Stubbs B, Vancampfort D, Hallgren M, et al. EPA guidance on physical activity as a treatment for severe mental illness: A meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry 2018; 54:124–44. DOI: 10.1016/j.eurpsy.2018.07.004. http://www.ncbi.nlm.nih.gov/pubmed/30257806.
• Bermejo I, Kriston L, Schneider F, et al. Sick leave and depression - determining factors and clinical effect in outpatient care. Psychiatry Res 2010; 180(2-3):68–73. DOI: 10.1016/j.psychres.2010.04.028. http://www.ncbi.nlm.nih.gov/pubmed/20494453.
• Sylvain C, Durand M-J, Maillette P, et al. How do general practitioners contribute to preventing long-term work disability of their patients suffering from depressive disorders? A qualitative study. BMC Fam Pract 2016; 17(71). DOI: 10.1186/s12875-016-0459-2. http://www.ncbi.nlm.nih.gov/pubmed/27267763.
• Macdonald S, Maxwell M, Wilson P, et al. "A powerful intervention: General practitioners'; use of sickness certification in depression". BMC Fam Pract 2012; 13(82). DOI: 10.1186/1471-2296-13-82. http://www.ncbi.nlm.nih.gov/pubmed/22877237.
• Aalbers S, Fusar-Poli L, Freeman RE, et al. Music therapy for depression. Cochrane Database Syst Rev 2017; 11(11):CD004517. DOI: 10.1002/14651858.CD004517.pub3. http://www.ncbi.nlm.nih.gov/pubmed/29144545.
• Meekums B, Karkou V, Nelson EA. Dance movement therapy for depression. Cochrane Database Syst Rev 2015(2):CD009895. DOI: 10.1002/14651858.CD009895.pub2. http://www.ncbi.nlm.nih.gov/pubmed/25695871.
• Firth J, Teasdale SB, Allott K, et al. The efficacy and safety of nutrient supplements in the treatment of mental disorders: A meta-review of meta-analyses of randomized controlled trials. World Psychiatry 2019; 18(3):308–24. DOI: 10.1002/wps.20672. http://www.ncbi.nlm.nih.gov/pubmed/31496103.
• Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl Psychiatry 2019; 9(1):190. DOI: 10.1038/s41398-019-0515-5. http://www.ncbi.nlm.nih.gov/pubmed/31383846.
• Deane KH, Jimoh OF, Biswas P, et al. Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: Systematic review and meta-analysis of randomised trials. Br J Psychiatry 2021; 218(3):135–42. DOI: 10.1192/bjp.2019.234. http://www.ncbi.nlm.nih.gov/pubmed/31647041.
• Luo X-D, Feng J-S, Yang Z, et al. High-dose omega-3 polyunsaturated fatty acid supplementation might be more superior than low-dose for major depressive disorder in early therapy period: A network meta-analysis. BMC Psychiatry 2020; 20(1):248. DOI: 10.1186/s12888-020-02656-3. http://www.ncbi.nlm.nih.gov/pubmed/32434488.
• Chambergo-Michilot D, Brañez-Condorena A, Falvy-Bockos I, et al. Efficacy of omega-3 supplementation on sertraline continuous therapy to reduce depression or anxiety symptoms: A systematic review and meta-analysis. Psychiatry Res 2021; 296:113652. DOI: 10.1016/j.psychres.2020.113652. http://www.ncbi.nlm.nih.gov/pubmed/33348198.
• Appleton KM, Sallis HM, Perry R, et al. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev 2015(11):CD004692. DOI: 10.1002/14651858.CD004692.pub4. http://www.ncbi.nlm.nih.gov/pubmed/26537796.
• Smith CA, Armour M, Lee MS, et al. Acupuncture for depression. Cochrane Database Syst Rev 2018; 3(3):CD004046. DOI: 10.1002/14651858.CD004046.pub4. http://www.ncbi.nlm.nih.gov/pubmed/29502347.
• Sonneck G, Kapusta N, Tomandl G, et al., editors. Krisenintervention und Suizidverhütung. 3rd ed. Wien: Facultas; 2016.
• Mann JJ, Michel CA, Auerbach RP. Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review. Am J Psychiatry 2021; 178(7):611–24. DOI: 10.1176/appi.ajp.2020.20060864. http://www.ncbi.nlm.nih.gov/pubmed/33596680.
• Dunster-Page C, Haddock G, Wainwright L, et al. The relationship between therapeutic alliance and patient's suicidal thoughts, self-harming behaviours and suicide attempts: A systematic review. J Affect Disord 2017; 223:165–74. DOI: 10.1016/j.jad.2017.07.040. http://www.ncbi.nlm.nih.gov/pubmed/28755624.
• Franklin JC, Ribeiro JD, Fox KR, et al. Risk factors for suicidal thoughts and behaviors: A meta-analysis of 50 years of research. Psychol Bull 2017; 143(2):187–232. DOI: 10.1037/bul0000084. http://www.ncbi.nlm.nih.gov/pubmed/27841450.
• McClatchey K, Murray J, Rowat A, et al. Risk Factors for Suicide and Suicidal Behavior Relevant to Emergency Health Care Settings: A Systematic Review of Post-2007 Reviews. Suicide Life Threat Behav 2017; 47(6):729–45. DOI: 10.1111/sltb.12336. http://www.ncbi.nlm.nih.gov/pubmed/28220516.
• McClatchey K, Murray J, Chouliara Z, et al. Protective Factors of Suicide and Suicidal Behavior Relevant to Emergency Healthcare Settings: A Systematic Review and Narrative Synthesis of Post-2007 Reviews. Arch Suicide Res 2019; 23(3):411–27. DOI: 10.1080/13811118.2018.1480983. http://www.ncbi.nlm.nih.gov/pubmed/30024351.
• Forkmann T, Teismann T, Glaesmer H, editors. Diagnostik von Suizidalität. Göttingen: Hogrefe; 2016 (Kompendien psychologische Diagnostik; Band 14).
• Witt KG, Hetrick SE, Rajaram G, et al. Psychosocial interventions for self-harm in adults. Cochrane Database Syst Rev 2021; 4(4):CD013668. DOI: 10.1002/14651858.CD013668.pub2. http://www.ncbi.nlm.nih.gov/pubmed/33884617.
• Briggs S, Netuveli G, Gould N, et al. The effectiveness of psychoanalytic/psychodynamic psychotherapy for reducing suicide attempts and self-harm: Systematic review and meta-analysis. Br J Psychiatry 2019; 214(6):320–8. DOI: 10.1192/bjp.2019.33. http://www.ncbi.nlm.nih.gov/pubmed/30816079.
• Raj S, Ghosh D, Verma SK, et al. The mindfulness trajectories of addressing suicidal behaviour: A systematic review. Int J Soc Psychiatry 2021; 67(5):507–19. DOI: 10.1177/0020764020960776. http://www.ncbi.nlm.nih.gov/pubmed/32998626.
• Tighe J, Nicholas J, Shand F, et al. Efficacy of Acceptance and Commitment Therapy in Reducing Suicidal Ideation and Deliberate Self-Harm: Systematic Review. JMIR Ment Health 2018; 5(2):e10732. DOI: 10.2196/10732. http://www.ncbi.nlm.nih.gov/pubmed/29941419.
• Riblet NB, Shiner B, Young-Xu Y, et al. Strategies to prevent death by suicide: Meta-analysis of randomised controlled trials. Br J Psychiatry 2017; 210(6):396–402. DOI: 10.1192/bjp.bp.116.187799. http://www.ncbi.nlm.nih.gov/pubmed/28428338.
• McCabe R, Garside R, Backhouse A, et al. Effectiveness of brief psychological interventions for suicidal presentations: A systematic review. BMC Psychiatry 2018; 18(1):120. DOI: 10.1186/s12888-018-1663-5. http://www.ncbi.nlm.nih.gov/pubmed/29724203.
• Doupnik SK, Rudd B, Schmutte T, et al. Association of Suicide Prevention Interventions With Subsequent Suicide Attempts, Linkage to Follow-up Care, and Depression Symptoms for Acute Care Settings: A Systematic Review and Meta-analysis. JAMA Psychiatry 2020; 77(10):1021–30. DOI: 10.1001/jamapsychiatry.2020.1586. http://www.ncbi.nlm.nih.gov/pubmed/32584936.
• Meerwijk EL, Parekh A, Oquendo MA, et al. Direct versus indirect psychosocial and behavioural interventions to prevent suicide and suicide attempts: A systematic review and meta-analysis. Lancet Psychiatry 2016; 3(6):544–54. DOI: 10.1016/S2215-0366(16)00064-X. http://www.ncbi.nlm.nih.gov/pubmed/27017086.
• Nuij C, van Ballegooijen W, Beurs D de, et al. Safety planning-type interventions for suicide prevention: Meta-analysis. Br J Psychiatry 2021; 219(2):419–26. DOI: 10.1192/bjp.2021.50.
• Ferguson M, Rhodes K, Loughhead M, et al. The Effectiveness of the Safety Planning Intervention for Adults Experiencing Suicide-Related Distress: A Systematic Review. Arch Suicide Res 2021:1–24. DOI: 10.1080/13811118.2021.1915217. http://www.ncbi.nlm.nih.gov/pubmed/33913799.
• Stanley B, Brown G, Brent DA, et al. Cognitive-behavioral therapy for suicide prevention (CBT-SP): Treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry 2009; 48(10):1005–13. DOI: 10.1097/CHI.0b013e3181b5dbfe. http://www.ncbi.nlm.nih.gov/pubmed/19730273.
• Fartacek C, Kralovec K, Pichler E-M, et al. Notfallpläne zur Rückfallprävention von suizidalem Verhalten. Suizidprophylaxe 2014; 41(2):68–73.
• Torok M, Han J, Baker S, et al. Suicide prevention using self-guided digital interventions: A systematic review and meta-analysis of randomised controlled trials. Lancet Digit Health 2020; 2(1):e25-e36. DOI: 10.1016/S2589-7500(19)30199-2. http://www.ncbi.nlm.nih.gov/pubmed/33328037.
• Malakouti SK, Rasouli N, Rezaeian M, et al. Effectiveness of self-help mobile telephone applications (apps) for suicide prevention: A systematic review. Med J Islam Repub Iran 2020; 34:85. DOI: 10.34171/mjiri.34.85. http://www.ncbi.nlm.nih.gov/pubmed/33306048.
• Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001(2):CD003013. http://www.ncbi.nlm.nih.gov/pubmed/11406061.
• Cipriani A, Pretty H, Hawton K, et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. Am J Psychiatry 2005; 162(10):1805–19. http://www.ncbi.nlm.nih.gov/pubmed/16199826.
• Cipriani A, Hawton K, Stockton S, et al. Lithium in the prevention of suicide in mood disorders: Updated systematic review and meta-analysis. BMJ 2013; 346:f3646. DOI: 10.1136/bmj.f3646. http://www.ncbi.nlm.nih.gov/pubmed/23814104.
• Börjesson J, Gøtzsche PC. Effect of lithium on suicide and mortality in mood disorders: A systematic review. Int J Risk Saf Med 2019; 30(3):155–66. DOI: 10.3233/JRS-190058. http://www.ncbi.nlm.nih.gov/pubmed/31381531.
• Witt KG, Hetrick SE, Rajaram G, et al. Pharmacological interventions for self-harm in adults. Cochrane Database Syst Rev 2021; 2021(3):361. DOI: 10.1002/14651858.CD013669.pub2. http://dx.doi.org/10.1002/14651858.CD013669.pub2.
• Siegel AN, Di Vincenzo JD, Brietzke E, et al. Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review. J Psychiatr Res 2021; 137:426–36. DOI: 10.1016/j.jpsychires.2021.03.009. http://www.ncbi.nlm.nih.gov/pubmed/33774537.
• Dean RL, Hurducas C, Hawton K, et al. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev 2021; 9:CD011612. DOI: 10.1002/14651858.CD011612.pub3. http://www.ncbi.nlm.nih.gov/pubmed/34510411.
• Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V: Esketamin (Depression, akute Kurzzeitbehandlung, Kombinationstherapie). 2021 [cited: 2021-10-28]. https://www.g-ba.de/downloads/39-261-4983/2021-08-19_AM-RL-XII_Esketamin_D-659_BAnz.pdf.
• Maguire L, Bullard T, Papa L. Ketamine for acute suicidality in the emergency department: A systematic review. Am J Emerg Med 2021; 43:54–8. DOI: 10.1016/j.ajem.2020.12.088. http://www.ncbi.nlm.nih.gov/pubmed/33524683.
• Bartoli F, Riboldi I, Crocamo C, et al. Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. Neurosci Biobehav Rev 2017; 77:232–6. DOI: 10.1016/j.neubiorev.2017.03.010. http://www.ncbi.nlm.nih.gov/pubmed/28342764.
• Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry 2020; 54(1):29–45. DOI: 10.1177/0004867419883341. http://www.ncbi.nlm.nih.gov/pubmed/31729893.
• Wilkinson ST, Ballard ED, Bloch MH, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry 2018; 175(2):150–8. DOI: 10.1176/appi.ajp.2017.17040472. http://www.ncbi.nlm.nih.gov/pubmed/28969441.
• Chen M-H, Lin W-C, Wu H-J, et al. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). J Affect Disord 2019; 251:162–9. DOI: 10.1016/j.jad.2019.03.075. http://www.ncbi.nlm.nih.gov/pubmed/30925267.
• Kucuker MU, Almorsy AG, Sonmez AI, et al. A Systematic Review of Neuromodulation Treatment Effects on Suicidality. Front Hum Neurosci 2021; 15:660926. DOI: 10.3389/fnhum.2021.660926. http://www.ncbi.nlm.nih.gov/pubmed/34248523.
• Chen Y, Magnin C, Brunelin J, et al. Can seizure therapies and noninvasive brain stimulations prevent suicidality? A systematic review. Brain Behav 2021; 11(5):e02144. DOI: 10.1002/brb3.2144. http://www.ncbi.nlm.nih.gov/pubmed/33838000.
• Chaudhary AM, Memon RI, Dar SK, et al. Suicide during Transition of Care: A Review of Targeted Interventions. Psychiatr Q 2020; 91(2):417–50. DOI: 10.1007/s11126-020-09712-x. http://www.ncbi.nlm.nih.gov/pubmed/31960191.
• Holst M, Harfst T, Schulz H. Die Versorgung von Patienten mit psychischen Störungen. In: Hoyer J, Knappe S, editors. Klinische Psychologie & Psychotherapie. 3rd. Berlin: Springer; 2020, p. 353–373.
• Bundesarbeitsgemeinschaft der medizinisch-beruflichen Rehabilitationseinrichtungen. www.mbreha.de[cited: 2021-11-10].
• Deutsche Rentenversicherung Bund (DRV-Bund). Reha-Therapiestandards Depressive Störungen: für die medizinische Rehabilitation der Rentenversicherung. 2016 [cited: 2021-11-09]. https://www.deutsche-rentenversicherung.de/SharedDocs/Downloads/DE/Experten/infos_reha_einrichtungen/quali_rehatherapiestandards/Depression/rts_depression_download.html.
• Deutsche Rentenversicherung Bund (DRV-Bund). RTS-Methodenreport Depressive Störungen. 2015 [cited: 2021-11-09]. https://www.deutsche-rentenversicherung.de/SharedDocs/Downloads/DE/Experten/infos_reha_einrichtungen/quali_rehatherapiestandards/Depression/rts_depression_methodenreport_download_2015.html.
• Steffanowski A. Meta-Analyse der Effekte stationärer psychosomatischer Rehabilitation: Mesta-Studie. Bern: Huber; 2007.
• Meyer V, Neu R, Köllner V. Effektivität berufsbezogener Psychotherapiekonzepte in der psychosomatischen Rehabilitation. In: Deutsche Rentenversicherung Bund (DRV-Bund), editor. 25. Rehabilitationswissenschaftliches Kolloquium. Deutscher Kongress für Rehabilitationsforschung Gesundheitssystem im Wandel - Perspektiven der Rehabilitation vom 29. Februar bis 2. März 2016 in Aachen; 2016, p. 455–456.
• Nübling R, Schmidt J, Kriz D. Routine-Assessment in der psychosomatischen Rehabilitation – Behandlungsergebnisse auf der Grundlage eines EDV-gestützten Routine-Assessment-Systems. In: Deutsche Rentenversicherung Bund (DRV-Bund), editor. 24. Rehabilitationswissenschaftliches Kolloquium. Deutscher Kongress für Rehabilitationsforschung. Psychische Störungen – Herausforderungen für Prävention und Rehabilitation vom 16. bis 18. März 2015 in Augsburg; 2015, p. 336–338.
• Vries U de, Petermann F, Lange M. Differenzielle Effekte stationärer psychosomatischer Rehabilitation. Phys Med Rehab Kuror 2011; 21(6):290–5. DOI: 10.1055/s-0031-1291369.
• Lange M, Franke W, Petermann F. Wer profitiert nicht von der psychosomatischen Rehabilitation? Rehabilitation (Stuttg) 2012; 51(6):392–7. DOI: 10.1055/s-0032-1304612. http://www.ncbi.nlm.nih.gov/pubmed/22689340.
• Albani C. Behandlungspfade in der Psychosomatik: Vom Projekt „Eilverfahren Psychosomatische Reha“ zur „Anschluss-Rehabilitation Psychosomatik“. Spektrum 2018(3):32–3.
• Marhoffer K, Haselmayr-Skusa U. Reha-Eilverfahren Psychosomatik: Gemeinsames Modellprojekt der DRV und der Schussental-Klinik Aulendorf. Spektrum 2018(3):30–1.
• Bundesarbeitsgemeinschaft für Rehabilitation (BAR), editor. Rehabilitation: Vom Antrag bis zur Nachsorge - für Ärzte, Psychologische Psychotherapeuten und andere Gesundheitsberufe. Berlin: Springer; 2018.
• Nieuwenhuijsen K, Faber B, Verbeek JH, et al. Interventions to improve return to work in depressed people. Cochrane Database Syst Rev 2014(12):CD006237. DOI: 10.1002/14651858.CD006237.pub3. http://www.ncbi.nlm.nih.gov/pubmed/25470301.
• Deutsche Rentenversicherung Bund (DRV-Bund). Rentenversicherung in Zahlen 2021. 2021 [cited: 2021-11-09]. https://www.deutsche-rentenversicherung.de/SharedDocs/Downloads/DE/Statistiken-und-Berichte/statistikpublikationen/rv_in_zahlen_2021.html.
• UPD Patientenberatung Deutschland. Monitor Patientenberatung 2019. 2019 [cited: 2021-11-10]. https://www.patientenberatung.de/dokumente/UPD_Patientenmonitor%202019.pdf.
• UPD Patientenberatung Deutschland. Monitor Patientenberatung 2020. 2020 [cited: 2021-11-10]. https://www.patientenberatung.de/dokumente/UPD%20Monitor%20Patientenberatung%202020.pdf.
• Gesetz zur Stärkung der Teilhabe und Selbstbestimmung von Menschen mit Behinderungen (Bundesteilhabegesetz – BTHG): vom 23. Dezember 2016. Bundesgesetzblatt Teil I 2016(66):3234–341.
• Wittchen HU, Winter S, Höfler M, et al. Häufigkeit und Erkennensrate von Depressionen in der hausärztlichen Praxis. Fortschr Med 2000(Sonderheft I):22–30.
• Melchior H, Schulz H, Härter M. Faktencheck Gesundheit. Regionale Unterschiede in der Diagnostik und Behandlung von Depressionen. 2014 [cited: 2021-11-22]. https://faktencheck-gesundheit.de/fileadmin/files/user_upload/Faktencheck_Depression_Studie.pdf.
• Trautmann S, Beesdo-Baum K. The Treatment of Depression in Primary Care. Dtsch Arztebl Int 2017; 114(43):721–8. DOI: 10.3238/arztebl.2017.0721. http://www.ncbi.nlm.nih.gov/pubmed/29143731.
• Sekera E, Archinard H, Stalder H. Depression. Strategien für die ambulante Medizin. Prim. Care 2004; 4:314–8.
• Gerste B, Günster C. Diagnosehäufigkeit und Inanspruchnahme von Gesundheitsleistungen. In: Klauber J, Günster C, Gerste B, Robra B-P, Schmacke N, editors. Schwerpunkt: Depression. Stuttgart: Schattauer; 2014, p. 257–308.
• Brown JV, Walton N, Meader N, et al. Pharmacy-based management for depression in adults. Cochrane Database Syst Rev 2019; 12:CD013299. DOI: 10.1002/14651858.CD013299.pub2. http://www.ncbi.nlm.nih.gov/pubmed/31868236.
• Davis B, Qian J, Ngorsuraches S, et al. The clinical impact of pharmacist services on mental health collaborative teams: A systematic review. J Am Pharm Assoc (2003) 2020; 60(5S):S44-S53. DOI: 10.1016/j.japh.2020.05.006. http://www.ncbi.nlm.nih.gov/pubmed/32600986.
• Leitliniengruppe Hessen, Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM). S3-Leitlinie Multimedikation: Registernummer 053–043, Version 2021-08. 2021 [cited: 2021-08-17]. https://www.awmf.org/leitlinien/detail/ll/053-043.html.
• Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Entlassmanagement. 2015 [cited: 2021-12-03]. https://www.g-ba.de/downloads/39-261-2415/2015-12-17_AM-RL_Entlassmanagement_BAnz.pdf.
• Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Heilmittel-Richtlinie: Verordnung im Rahmen des Entlassmanagements. 2015 [cited: 2021-12-03]. https://www.g-ba.de/downloads/39-261-2448/2015-12-17_2016-05-19_HeilM-RL_Entlassmanagement_konsolidiert_BAnz.pdf.
• Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Häusliche Krankenpflege-Richtlinie: Verordnung im Rahmen des Entlassmanagements. 2015 [cited: 2021-12-03]. https://www.g-ba.de/downloads/39-261-2449/2015-12-17_HKP-RL_Entlassmanagement_BAnz.pdf.
• Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der ArbeitsunfähigkeitsRichtlinie: Feststellung der Arbeitsunfähigkeit im Rahmen des Entlassmanagements. 2015 [cited: 2021-12-03]. https://www.g-ba.de/downloads/39-261-2450/2015-12-17_AU-RL_Entlassmanagement_BAnz.pdf.
• Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der SoziotherapieRichtlinie: Verordnung im Rahmen des Entlassmanagements. 2015 [cited: 2021-12-03]. https://www.g-ba.de/downloads/39-261-2442/2015-12-17_ST-RL_Entlassmanagement_BAnz.pdf.
• Crawford MJ. Suicide following discharge from in-patient psychiatric care. Adv. psychiatr. treat 2004; 10(6):434–8. DOI: 10.1192/apt.10.6.434.
• Kassenärztliche Bundesvereinigung (KBV). Verordnen im Rahmen des Entlassmanagements nach § 39 Abs. 1A SGB V. 2017 [cited: 2021-12-03]. https://www.kbv.de/media/sp/Verordnen_im_Rahmen_des_Entlassmanagements.pdf.
• Archer J, Bower P, Gilbody S, et al. Collaborative care for depression and anxiety problems. Cochrane Database Syst Rev 2012; 10:CD006525. DOI: 10.1002/14651858.CD006525.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23076925.
• van Eck Sluijs JF, Castelijns H, Eijsbroek V, et al. Illness burden and physical outcomes associated with collaborative care in patients with comorbid depressive disorder in chronic medical conditions: A systematic review and meta-analysis. Gen Hosp Psychiatry 2018; 50:1–14. DOI: 10.1016/j.genhosppsych.2017.08.003. http://www.ncbi.nlm.nih.gov/pubmed/28957682.
• Panagioti M, Bower P, Kontopantelis E, et al. Association Between Chronic Physical Conditions and the Effectiveness of Collaborative Care for Depression: An Individual Participant Data Meta-analysis. JAMA Psychiatry 2016; 73(9):978–89. DOI: 10.1001/jamapsychiatry.2016.1794. http://www.ncbi.nlm.nih.gov/pubmed/27602561.
• Hudson JL, Bower P, Kontopantelis E, et al. Impact of telephone delivered case-management on the effectiveness of collaborative care for depression and anti-depressant use: A systematic review and meta-regression. PLoS One 2019; 14(6):e0217948. DOI: 10.1371/journal.pone.0217948. http://www.ncbi.nlm.nih.gov/pubmed/31199827.
• Grigoroglou C, van der Feltz-Cornelis C, Hodkinson A, et al. Effectiveness of collaborative care in reducing suicidal ideation: An individual participant data meta-analysis. Gen Hosp Psychiatry 2021; 71:27–35. DOI: 10.1016/j.genhosppsych.2021.04.004. http://www.ncbi.nlm.nih.gov/pubmed/33915444.
• Dieterich M, Irving CB, Bergman H, et al. Intensive case management for severe mental illness. Cochrane Database Syst Rev 2017; 1(1):CD007906. DOI: 10.1002/14651858.CD007906.pub3. http://www.ncbi.nlm.nih.gov/pubmed/28067944. http://dx.doi.org/10.1002/14651858.CD007906.pub3.
• Maehder K, Werner S, Weigel A, et al. How do care providers evaluate collaboration? - qualitative process evaluation of a cluster-randomized controlled trial of collaborative and stepped care for patients with mental disorders. BMC Psychiatry 2021; 21(1):296. DOI: 10.1186/s12888-021-03274-3. http://www.ncbi.nlm.nih.gov/pubmed/34098913.
• Hölzel LP, Bjerregaard F, Bleich C, et al. Coordinated Treatment of Depression in Elderly People in Primary Care. Dtsch Arztebl Int 2018; 115(44):741–7. DOI: 10.3238/arztebl.2018.0741. http://www.ncbi.nlm.nih.gov/pubmed/30565544.
• Gensichen J, Korff M von, Peitz M, et al. Case management for depression by health care assistants in small primary care practices: A cluster randomized trial. Ann Intern Med 2009; 151(6):369–78. DOI: 10.7326/0003-4819-151-6-200909150-00001. http://www.ncbi.nlm.nih.gov/pubmed/19755362.
• Zimmermann T, Puschmann E, van den Bussche H, et al. Collaborative nurse-led self-management support for primary care patients with anxiety, depressive or somatic symptoms: Cluster-randomised controlled trial (findings of the SMADS study). Int J Nurs Stud 2016; 63:101–11. DOI: 10.1016/j.ijnurstu.2016.08.007. http://www.ncbi.nlm.nih.gov/pubmed/27611093.
• Schubert T, Vogelmann T, Pieper D, et al. Kosteneffektivität eines telefonischen Versorgungsmanagementprogramms bei psychischen Erkrankungen aus Sicht der gesetzlichen Krankenversicherung. Gesundh ökon Qual manag 2015; 20(06):286–92. DOI: 10.1055/s-0034-1399458. https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0034-1399458.
• Härter M, Watzke B, Daubmann A, et al. Guideline-based stepped and collaborative care for patients with depression in a cluster-randomised trial. Sci Rep 2018; 8(1):9389. DOI: 10.1038/s41598-018-27470-6. http://www.ncbi.nlm.nih.gov/pubmed/29925893.
• Berghöfer A, Hartwich A, Bauer M, et al. Efficacy of a systematic depression management program in high utilizers of primary care: A randomized trial. BMC Health Serv Res 2012; 12:298. DOI: 10.1186/1472-6963-12-298. http://www.ncbi.nlm.nih.gov/pubmed/22943609.
• Kivelitz L, Kriston L, Christalle E, et al. Effectiveness of telephone-based aftercare case management for adult patients with unipolar depression compared to usual care: A randomized controlled trial. PLoS One 2017; 12(10):e0186967. DOI: 10.1371/journal.pone.0186967. http://www.ncbi.nlm.nih.gov/pubmed/29077724.
• Gensichen J, Guethlin C, Sarmand N, et al. Patients' perspectives on depression case management in general practice - a qualitative study. Patient Educ Couns 2012; 86(1):114–9. DOI: 10.1016/j.pec.2011.02.020. http://www.ncbi.nlm.nih.gov/pubmed/21474266.
• Härter M, Heddaeus D, Steinmann M, et al. Collaborative and stepped care for depression: Development of a model project within the Hamburg Network for Mental Health (psychenet.de). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2015; 58(4-5):420–9. DOI: 10.1007/s00103-015-2124-7. http://www.ncbi.nlm.nih.gov/pubmed/25698121.
• Robert Koch-Institut (RKI), editor. Psychotherapeutische Versorgung. Berlin: RKI; 2008 (Gesundheitsberichterstattung des Bundes; 41).
• Wang PS, Angermeyer M, Borges G, et al. Delay and failure in treatment seeking after first onset of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007; 6(3):177–85. http://www.ncbi.nlm.nih.gov/pubmed/18188443.
• Gemeinsamer Bundesausschuss (G-BA). Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über die 17. Änderung der DMP-Anforderungen-Richtlinie (DMP-A-RL): Änderung der Anlage 2, Ergänzung der Anlage 17 (DMP Depression) und der Anlage 18 (Depression – Dokumentation). 2019 [cited: 2021-11-23]. https://www.g-ba.de/downloads/40-268-6017/2019-08-15_DMP-A-RL_Depression_TrG.pdf.
• Schomerus G, Matschinger H, Angermeyer MC. The stigma of psychiatric treatment and help-seeking intentions for depression. Eur Arch Psychiatry Clin Neurosci 2009; 259(5):298–306. DOI: 10.1007/s00406-009-0870-y. http://www.ncbi.nlm.nih.gov/pubmed/19224105.
• Beck AT, Steer RA, Brown GK. Beck Depression Inventory. Manual. 2nd ed. San Antonio: Psychological Corp; 1996.
• Hautzinger M, Keller F, Kühner C. BDI-II-Depressionsinventar. 2nd ed. Frankfurt: Harcourt Test Serv; 2006.
• Herrmann-Lingen C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale - Deutsche Version (HADS-D). Manual. Berlin: Huber; 1993.
• Herrmann-Lingen C., Buss U., Snaith R.P. Hospital Anxiety and Depression Scale - deutsche Version (HADS-D). 3rd ed. Bern: Huber; 2011.
• Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clin Gerontologist 1986; 5(1-2):165–73.
• Fischer GC. Ambulantes geriatrischgerontologisches Screening in der Primärversorgung. Hannover: Norddeutscher Forschungsverbund Public Health; 1988.
• Gauggel S, Birkner B. Validität und Reliabilität einer deutschen Version der Geriatrischen Depressionsskala (GDS). Z Klin Psych Psychother 1999; 28(1):18–27. DOI: 10.1026//0084-5345.28.1.18.
• Zimmerman M, Coryell W, Corenthal C, et al. A self-report scale to diagnose major depressive disorder. Arch Gen Psychiatry 1986; 43(11):1076–81. DOI: 10.1001/archpsyc.1986.01800110062008. http://www.ncbi.nlm.nih.gov/pubmed/3767597.
• Kühner C. Fragebogen zur Depressionsdiagnostik nach DSM-IV (FDD-DSM-IV). Göttingen: Hogrefe; 1997.
• Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas 2016; 1(3):385–401. DOI: 10.1177/014662167700100306.
• Lewinsohn PM, Seeley JR, Roberts RE, et al. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging 1997; 12(2):277–87. DOI: 10.1037//0882-7974.12.2.277. http://www.ncbi.nlm.nih.gov/pubmed/9189988.
• Eaton WW, Smith C, Ybarra M, et al. Center for Epidemiologic Studies Depression Scale: Review and Revision (CESD and CESD–R). In: Maruish ME, editor. Instruments for adults. 3rd: Taylor and Francis; 2004, p. 363–377.
• Hautzinger M, Bailer M, Hofmeister D, et al. ADS: Die Allgemeine Depressionsskala. 2nd ed. Göttingen: Hogrefe; 2012.
• Hamilton M. A rating scale for depression. J Neurol. Neurosurg. Psychiatry 1960; 23:56–62. http://www.ncbi.nlm.nih.gov/pubmed/14399272.
• Bech P, Rafaelsen OJ. The melancholia scale development, consistency, validity and utility. In: Satorius N, Ban TA, editors. Assessment of depression. Berlin: Springer; 1986.
• Stieglitz RD, Wolfersdorf M, Metzger R, et al. Stationäre Behandlung depressiver Patienten. Konzeptuelle Überlegungen und Ergebnisse eines Pilotprojekts zur Qualitätssicherung in Baden-Württemberg. Nervenarzt 1998; 69(1):59–65. http://www.ncbi.nlm.nih.gov/pubmed/9522334.
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–9. http://www.ncbi.nlm.nih.gov/pubmed/444788.
• Neumann N, Schulte R. Montgomery-Asperg-Depressions-Rating-Skala zur psychometrischen Beurteilung depressiver Syndrome. Deutsche Fassung. Erlangen: Perimed-Fachbuch; 1989.
• Rush AJ, Carmody T. The inventory of depressive symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000; 9(2):45-59. DOI: 10.1002/mpr.79.
• Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: A sequenced treatment alternatives to relieve depression trial report. Biol. Psychiatry 2006; 59(6):493–501. DOI: 10.1016/j.biopsych.2005.08.022. http://www.ncbi.nlm.nih.gov/pubmed/16199008.
• Lamoureux BE, Linardatos E, Fresco DM, et al. Using the QIDS-SR16 to identify major depressive disorder in primary care medical patients. Behav Ther 2010; 41(3):423–31. DOI: 10.1016/j.beth.2009.12.002. http://www.ncbi.nlm.nih.gov/pubmed/20569790.
• Reilly TJ, MacGillivray SA, Reid IC, et al. Psychometric properties of the 16-item Quick Inventory of Depressive Symptomatology: A systematic review and meta-analysis. J Psychiatr Res 2015; 60:132–40. DOI: 10.1016/j.jpsychires.2014.09.008. http://www.ncbi.nlm.nih.gov/pubmed/25300442.
• Roniger A, Späth C, Schweiger U, et al. A Psychometric Evaluation of the German Version of the Quick Inventory of Depressive Symptomatology (QIDS-SR16) in Outpatients with Depression. Fortschr Neurol Psychiatr 2015; 83(12):e17-22. DOI: 10.1055/s-0041-110203. http://www.ncbi.nlm.nih.gov/pubmed/26714254.
• Löwe B, Unützer J, Callahan CM, et al. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care 2004; 42(12):1194–201. DOI: 10.1097/00005650-200412000-00006. http://www.ncbi.nlm.nih.gov/pubmed/15550799.
• Hiroe T, Kojima M, Yamamoto I, et al. Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psychiatry Res 2005; 135(3):229–35. http://www.ncbi.nlm.nih.gov/pubmed/15996749.
• Button KS, Kounali D, Thomas L, et al. Minimal clinically important difference on the Beck Depression Inventory--II according to the patient's perspective. Psychol Med 2015; 45(15):3269–79. DOI: 10.1017/S0033291715001270. http://www.ncbi.nlm.nih.gov/pubmed/26165748.
• Lemay KR, Tulloch HE, Pipe AL, et al. Establishing the Minimal Clinically Important Difference for the Hospital Anxiety and Depression Scale in Patients With Cardiovascular Disease. J Cardiopulm Rehabil Prev 2018; 39(6):E6-E11. DOI: 10.1097/HCR.0000000000000379. http://www.ncbi.nlm.nih.gov/pubmed/30489438.
• Puhan MA, Frey M, Buchi S, et al. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes 2008; 6:46. DOI: 10.1186/1477-7525-6-46. http://www.ncbi.nlm.nih.gov/pubmed/18597689.
• Haase I, Winkeler M, Imgart H. Anchor-based ascertaining of meaningful changes in depressive symptoms using the example of the German short form of the CES-D. Neuropsychiatr 2016; 30(2):82–91. DOI: 10.1007/s40211-016-0184-z. http://www.ncbi.nlm.nih.gov/pubmed/27300327.
• Kroenke K, Stump TE, Kean J, et al. PROMIS 4-item measures and numeric rating scales efficiently assess SPADE symptoms compared with legacy measures. J Clin Epidemiol 2019; 115:116–24. DOI: 10.1016/j.jclinepi.2019.06.018. http://www.ncbi.nlm.nih.gov/pubmed/31330252.
• Shekelle PG, MacLean CH, Morton SC, et al. Assessing care of vulnerable elders: Methods for developing quality indicators. Ann Intern Med 2001; 135(8 Pt 2):647–52. http://www.ncbi.nlm.nih.gov/pubmed/11601947.
• Kroenke K, Yu Z, Wu J, et al. Operating characteristics of PROMIS four-item depression and anxiety scales in primary care patients with chronic pain. Pain Med 2014; 15(11):1892–901. DOI: 10.1111/pme.12537. http://www.ncbi.nlm.nih.gov/pubmed/25138978.
• Khan SA, Revicki DA, Hassan M, et al. Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder. J Clin Psychiatry 2016; 77(8):1080–6. DOI: 10.4088/JCP.14m09719. http://www.ncbi.nlm.nih.gov/pubmed/26579723.
• Amri I, Millier A, Toumi M. Minimum Clinically Important Difference in the Calgary Depression Scale for Schizophrenia. Value Health 2014; 17(7):A766. DOI: 10.1016/j.jval.2014.08.288. http://www.ncbi.nlm.nih.gov/pubmed/27202813.
• National Collaborating Centre for Mental Health, National Institute for Clinical Excellence (NICE). Depression: Management of depression in primary and secondary care. Clinical Guideline 23. 2004 [cited: 2006-05-22]. http://www.nice.org.uk/page.aspx?o=235213.
• Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin 2008; 24(5):1329–35. DOI: 10.1185/030079908x291958. http://www.ncbi.nlm.nih.gov/pubmed/18377706.
• Furukawa T, McGuire H, Barbui C. Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev 2003(3):CD003197. http://www.ncbi.nlm.nih.gov/pubmed/12917952.

Inhalt

• Informationen zur aktuellen Version
  • Übersicht noch ausstehender Themen (Änderungen vorbehalten)
  • Änderungsprotokoll
• 1 Grundlagen
  • 1.1  Definition und Klassifikation
  • 1.2  Deskriptive Epidemiologie
  • 1.3  Ätiopathogenese und Risikofaktoren
  • 1.4  Verlaufsformen und prognostische Faktoren
• 2 Diagnostik und Monitoring
  • 2.1 Diagnostischer Algorithmus
  • 2.2 Erkennen depressiver Störungen
  • 2.3 Diagnosestellung
  • 2.4 Differentialdiagnostik
  • 2.5 Erfassung von Komorbidität und Medikamentenanamnese
  • 2.6 Erfassung von psychosozialen Aspekten, Aktivität und Teilhabe
  • 2.7 Erfassung von Suizidalität
  • 2.8 Verlaufsdiagnostik, Monitoring
  • 2.9 Diagnostisches Vorgehen bei Nichtansprechen
• 3 Therapieplanung
  • 3.1  Behandlungsphasen und Behandlungsoptionen
  • 3.2  Behandlungsziele und klinische Endpunkte
  • 3.3  Aufklärung und Information der Patient*innen
  • 3.4  Partizipative Entscheidungsfindung
  • 3.5  Mitarbeit der Patient*innen
  • 3.6  Einbindung von Angehörigen
• 4 Therapieoptionen und Therapieprinzipien
  • 4.1  Psychoedukation und Schulungen
  • 4.2  Niedrigintensive Interventionen: Optionen und Versorgungsstrukturen
  • 4.3  Internet- und mobilbasierte Interventionen: Optionen und Prinzipien
  • 4.4  Medikamentöse Therapie: Optionen und Prinzipien
  • 4.5  Psychotherapie: Optionen und Prinzipien
  • 4.6  Neurostimulatorische Verfahren: Beschreibung und Verfügbarkeit
  • 4.7  Psychosoziale Therapien: Beschreibung und Zugang
  • 4.8  Unterstützende nicht-medikamentöse Therapieverfahren
• 5 Behandlung bei akuter depressiver Episode
  • 5.1 Behandlung bei leichten depressiven Episoden
  • 5.2 Behandlung bei mittelgradigen depressiven Episoden
  • 5.3 Behandlung bei schweren depressiven Episoden
  • 5.4 Psychotische Depression
• 6 Erhaltungstherapie und Rezidivprophylaxe
  • 6.1  Medikamentöse Erhaltungstherapie
  • 6.2  Medikamentöse Rezidivprophylaxe
  • 6.3 Psychotherapeutische Weiterführung und Rezidivprophylaxe
  • 6.4  Erhaltungstherapie und Rezidivprophylaxe mit Kombinationsbehandlung
  • 6.5  Rezidivprophylaxe mit Internet- und mobilbasierten Interventionen
• 7 Maßnahmen bei Nichtansprechen und Therapieresistenz
  • 7.1 Vorgehen bei Nichtansprechen einer medikamentösen Therapie
  • 7.2 Vorgehen bei Nichtansprechen einer Psychotherapie
  • 7.3 Weitere Optionen bei mehrfachem Nichtansprechen
• 8 Behandlung chronischer Formen
• 9 Psychosoziale Therapien und unterstützende Maßnahmen
  • 9.1 Ergotherapie
  • 9.2 Soziotherapie
  • 9.3 Selbsthilfe und Peer Support
  • 9.4 Lichttherapie
  • 9.5 Wachtherapie
  • 9.6 Bewegungs- und Sporttherapien
  • 9.7 Psychiatrische Häusliche Krankenpflege
  • 9.8 Arbeitsunfähigkeit
  • 9.9 Künstlerische Therapien
  • 9.10 Komplementär- und alternativmedizinische Interventionen
• 10 Spezielle klinische Situationen (folgt)
  • 10.1 Ältere Patient*innen
  • 10.2 Kultur- und migrationsspezifische Aspekte
  • 10.3 Genderspezifische Aspekte
  • 10.4 Peripartale Depressionen
  • 10.5 Prämenstruelle dysphorische Störung
  • 10.6 Perimenopausale Depressionen
• 11 Komorbidität (folgt)
• 12 Management bei Suizidalität und anderen Notfallsituationen
  • 12.1 Vorgehen bei Suizidalität
  • 12.2 Krisenintervention und Psychotherapie
  • 12.3 Medikamentöse Therapie
  • 12.4 Neurostimulatorische Verfahren
  • 12.5 Nachsorge nach Suizidalität
  • 12.6 Andere Notfälle
• 13 Medizinische Rehabilitation und Leistungen zur Teilhabe
  • 13.1 Versorgungssituation in Deutschland
  • 13.2 Medizinische Rehabilitation
  • 13.3 Leistungen zur Teilhabe am Arbeitsleben und zur Teilhabe an Bildung
  • 13.4 Soziale Teilhabe
• 14 Versorgungskoordination
  • 14.1 Versorgungsstrukturen in Deutschland
  • 14.2 Ambulante Versorgungskoordination und Überweisungsindikationen
  • 14.3 Koordination der sektorenübergreifenden Versorgung
  • 14.4 Strukturierte und komplexe Versorgungsformen
• 15 Forschungsbedarf
• Methodik
  • I Einführung
  • II Zielsetzung
  • III Organisation und methodisches Vorgehen
  • IV Methodenkritische Aspekte
• Impressum
  • Herausgeber
  • Mittragende Organisationen
  • Redaktion und Pflege
  • Korrespondenz
  • Gültigkeitsdauer und Fortschreibung
  • Fassungen der Leitlinie
  • Bitte wie folgt zitieren
  • Autor*innen
  • Methodische Begleitung und Koordination
• Anhang 1: Schwellenwerte bei psychometrischen Testverfahren
• Anhang 2: Ankerbasierte Referenzwerte zur minimalen klinischen relevanten Differenz (MCID) psychometrischer Testverfahren
• Anhang 3: Empfehlungen zu Dosierung, Plasmaspiegel und Monitoring (TDM) bei medikamentöser Therapie der unipolaren Depression
• Anhang 4: Antidepressiva: Neben- und Wechselwirkungen, Kontraindikationen
• Tabellenverzeichnis
• Abbildungsverzeichnis
• Abkürzungsverzeichnis
• Patientenblätter
• Literatur